Horizon Technology Finance (HRZN) 10-Q 2 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 02, 2023
Document Information [Line Items]
Entity Central Index Key	0001487428
Entity Registrant Name	Horizon Technology Finance Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	814-00802
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-2114934
Entity Address, Address Line One	312 Farmington Avenue
Entity Address, City or Town	Farmington
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06032
City Area Code	860
Local Phone Number	676‑8654
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,656,554
The 6.25% Notes due 2027 [Member]
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2027
Trading Symbol	HTFC
Security Exchange Name	NYSE
The 4.875% Notes due 2026 [Member]
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2026
Trading Symbol	HTFB
Security Exchange Name	NYSE
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HRZN
Security Exchange Name	NASDAQ

Consolidated Statements of Asse

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Investments at fair value	$ 715,312	$ 720,026
Cash	19,844	20,612
Investments in money market funds	23,698	7,066
Restricted investments in money market funds	2,987	2,788
Interest receivable	13,843	13,573
Other assets	2,554	2,761
Total assets	778,238	766,826
Liabilities
Borrowings (Note 7)	439,645	434,078
Distributions payable	9,365	9,159
Base management fee payable (Note 3)	1,059	1,065
Incentive fee payable (Note 3)	2,978	1,392
Other accrued expenses	3,508	2,684
Total liabilities	456,555	448,378
Commitments and contingencies (Notes 3 and 8)
Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 28,544,822 and 27,920,838 shares issued and 28,377,357 and 27,753,373 shares outstanding as of March 31, 2023 and December 31, 2022, respectively	30	29
Paid-in capital in excess of par	393,312	385,921
Distributable earnings (loss)	(71,659)	(67,502)
Total net assets	321,683	318,448
Total liabilities and net assets	$ 778,238	$ 766,826
Net asset value per common share (in dollars per share)	$ 11.34	$ 11.47
Investment, Unaffiliated Issuer [Member]
Assets
Investments at fair value	$ 714,466	$ 720,026
Investment, Affiliated Issuer, Noncontrolled [Member]
Assets
Investments at fair value	$ 846	$ 0

Consolidated Statements of As_2

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments at cost	$ 724,162	$ 721,248
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares oustanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	28,544,822	27,920,838
Common stock, shares outstanding (in shares)	28,377,357	27,753,373
Investment, Unaffiliated Issuer [Member]
Investments at cost	$ 724,162	$ 721,248
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at cost	$ 0	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investment income
Total investment income	$ 28,037	$ 14,204
Expenses
Interest expense	7,120	3,424
Base management fee (Note 3)	3,201	2,244
Performance based incentive fee (Note 3)	2,978	1,424
Administrative fee (Note 3)	440	362
Professional fees	658	577
General and administrative	445	344
Total expenses	14,842	8,375
Net investment income before excise tax	13,195	5,829
Provision for excise tax	184	100
Net investment income	13,011	5,729
Net realized and unrealized loss
Net realized (loss) gain on investments	(168)	30
Net unrealized (depreciation) appreciation on investments	(7,537)	(2,237)
Net realized and unrealized loss	(7,705)	(2,207)
Net increase in net assets resulting from operations	$ 5,306	$ 3,522
Net investment income per common share (in dollars per share)	$ 0.46	$ 0.26
Net increase in net assets resulting from operations per common share (in dollars per share)	0.19	0.16
Distributions declared per share (in dollars per share)	$ 0.33	$ 0.30
Weighted average shares outstanding (in shares)	28,227,100	21,904,160
Investment, Unaffiliated Issuer [Member]
Investment income
Interest income on non-affiliate investments	$ 27,399	$ 13,853
Fee income on non-affiliate investments	638	351
Net realized and unrealized loss
Net realized (loss) gain on investments	(168)	30
Net unrealized (depreciation) appreciation on investments	(8,383)	(2,287)
Investment, Affiliated Issuer, Noncontrolled [Member]
Net realized and unrealized loss
Net realized (loss) gain on investments	0
Net unrealized (depreciation) appreciation on investments	846	0
Investment, Affiliated Issuer, Controlled [Member]
Net realized and unrealized loss
Net realized (loss) gain on investments		0
Net unrealized (depreciation) appreciation on investments	$ 0	$ 50

Consolidated Statements of Chan

Consolidated Statements of Changes in Net Assets (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Common Stock Outstanding [Member]
Balance (in shares)	27,753,373	21,217,460
Issuance of common stock, net of offering costs (in shares)	605,848	2,750,171
Issuance of common stock under dividend reinvestment plan (in shares)	18,136	9,506
Balance (in shares)	28,377,357	23,977,137
Common Stock [Member]
Balance	$ 29	$ 22
Issuance of common stock, net of offering costs	1	3
Net investment income, net of excise tax	0	0
Net realized gain (loss) on investments	0	0
Net unrealized depreciation on investments	0	0
Issuance of common stock under dividend reinvestment plan	0	0
Distributions declared	0	0
Balance	30	25
Additional Paid-in Capital [Member]
Balance	385,921	301,359
Issuance of common stock, net of offering costs	7,173	38,184
Net investment income, net of excise tax	0	0
Net realized gain (loss) on investments	0	0
Net unrealized depreciation on investments	0	0
Issuance of common stock under dividend reinvestment plan	218	145
Distributions declared	0	0
Balance	393,312	339,688
Retained Earnings [Member]
Balance	(67,502)	(56,046)
Issuance of common stock, net of offering costs	0	0
Net investment income, net of excise tax	13,011	5,729
Net realized gain (loss) on investments	(168)	30
Net unrealized depreciation on investments	(7,537)	(2,237)
Issuance of common stock under dividend reinvestment plan	0	0
Distributions declared	(9,463)	(7,200)
Balance	(71,659)	(59,724)
Balance	318,448	245,335
Issuance of common stock, net of offering costs	7,174	38,187
Net investment income, net of excise tax	13,011	5,729
Net realized gain (loss) on investments	(168)	30
Net unrealized depreciation on investments	(7,537)	(2,237)
Issuance of common stock under dividend reinvestment plan	218	145
Distributions declared	(9,463)	(7,200)
Balance	$ 321,683	$ 279,989

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net increase in net assets resulting from operations	$ 5,306	$ 3,522
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Amortization of debt issuance costs	478	336
Net realized loss (gain) on investments	168	(30)
Net unrealized depreciation on investments	7,537	2,237
Purchase of investments	(47,008)	(94,485)
Principal payments received on investments	39,756	14,145
Payment-in-kind interest on investments	(1,204)	0
Proceeds from sale of investments	6,520	21,280
Changes in assets and liabilities:
Decrease (increase) in interest receivable	840	(866)
Increase in end-of-term payments	(1,017)	(1,285)
Decrease in unearned income	(1,148)	(81)
Decrease in other assets	98	652
Increase (decrease) in other accrued expenses	824	(274)
(Decrease) increase in base management fee payable	(6)	79
Increase (decrease) in incentive fee payable	1,586	(591)
Net cash provided by (used in) operating activities	12,730	(55,361)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs	7,174	38,187
Advances on Credit Facilities	10,000	25,000
Repayment of Credit Facilities	0	(20,000)
Debt issuance costs	(19)	(550)
Distributions paid	(9,039)	(6,227)
Net cash provided by financing activities	3,333	24,058
Net increase (decrease) in cash, cash equivalents and restricted cash	16,063	(31,303)
Cash, cash equivalents and restricted cash:
Beginning of period	30,466	47,281
End of period	46,529	15,978
Supplemental disclosure of cash flow information:
Cash paid for interest	6,623	3,044
Supplemental non-cash investing and financing activities:
Warrant investments received and recorded as unearned income	141	1,174
Distributions payable	9,365	7,193
End-of-term payments receivable	10,799	6,522
Non-cash income	3,944	1,424
Cash	19,844	12,452
Investments in money market funds	23,698	2,011
Restricted investments in money market funds	2,987	1,515
Total cash, cash equivalents and restricted cash	46,529	15,978
Asset-backed Notes 2019 [Member]
Cash flows from financing activities:
Repayment of notes	$ (4,783)	$ (12,352)

Consolidated Schedule of Invest

Consolidated Schedule of Investments (Unaudited)	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Schedule of Investments [Text Block]	March 31, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 222.1% Non-Affiliate Debt Investments — 212.8% Non-Affiliate Debt Investments — Life Science — 95.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,913 $ 2,860 $ 2,779 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,832 2,752 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,416 1,375 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,829 2,749 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,829 2,749 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,412 1,370 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,412 1,370 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,895 4,895 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,967 4,967 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,977 2,977 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,967 4,967 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,970 4,970 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,980 2,980 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.57 % Libor 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,965 1,965 Term Loan 12.57 % Libor 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,966 1,966 Term Loan 12.57 % Libor 4.72 % 9.75 % - 5.00 % November 1, 2025 5,000 4,930 4,930 Term Loan 12.57 % Libor 4.72 % 9.75 % - 5.00 % May 1, 2026 5,000 4,921 4,921 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 10,000 9,880 9,880 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 15,000 14,819 14,819 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 6,000 5,928 5,928 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 6,000 5,928 5,928 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,000 3,952 3,952 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,000 3,952 3,952 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 4,500 4,371 4,352 Term Loan 13.75 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,250 2,187 2,177 IMV Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,000 4,951 4,759 Term Loan 13.75 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,476 2,380 Term Loan 13.75 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,953 4,761 Term Loan 13.75 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,953 4,761 KSQ Therapeutics, Inc. (2) (12) Biotechnology Term Loan 12.75 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,082 6,082 Term Loan 12.75 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,182 6,182 Native Microbials, Inc (2) (12) Biotechnology Term Loan 13.25 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,707 3,707 Term Loan 13.25 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,472 2,472 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,714 9,714 Term Loan 13.75 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,702 3,702 Term Loan 13.75 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,702 3,702 Provivi, Inc. (2)(12) Biotechnology Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,667 4,606 4,606 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,667 4,606 4,606 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,287 2,287 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,287 2,287 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) March 31, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 13.50 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 5,000 4,922 4,922 Term Loan 13.50 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,500 2,461 2,461 Aerobiotix, LLC (2)(12) Medical Device Term Loan 14.25 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,467 2,361 Term Loan 14.25 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,467 2,361 Ceribell, Inc. (2)(12) Medical Device Term Loan 11.25 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,977 4,977 Term Loan 11.25 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,977 4,977 Term Loan 11.25 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,481 2,481 Term Loan 11.25 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,481 2,481 Cognoa, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 5,000 4,940 4,940 Term Loan 13.50 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,500 2,470 2,470 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 12.67 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,904 3,904 Term Loan 12.67 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,904 3,904 Corinth Medtech, Inc. (2)(12) Medical Device Term Loan 13.00 % (11) Prime 5.25 % 8.50 % - 20.00 % June 30, 2023 2,528 2,528 2,528 Term Loan 13.00 % (11) Prime 5.25 % 8.50 % - 20.00 % June 30, 2023 2,528 2,528 2,528 Term Loan 13.00 % (11) Prime 5.25 % 8.50 % - 50.00 % June 30, 2023 200 200 200 CSA Medical, Inc. (2)(12) Medical Device Term Loan 12.87 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 1,250 1,239 1,239 Term Loan 12.87 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 83 83 83 Term Loan 12.87 % Libor 8.20 % 10.00 % - 5.00 % March 1, 2024 1,600 1,587 1,587 InfoBionic, Inc. (2)(12) Medical Device Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 2,771 2,715 2,715 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 977 977 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,946 4,946 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,946 4,946 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,940 4,940 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,941 4,941 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,920 4,920 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,920 4,920 Robin Healthcare, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,413 3,413 Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,463 3,463 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 12.50 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,601 3,601 Term Loan 12.50 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,710 3,710 Sonex Health, Inc. (2)(12) Medical Device Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % April 1, 2026 2,500 2,459 2,459 Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % May 1, 2026 2,500 2,458 2,458 Spineology, Inc. (2)(12) Medical Device Term Loan 15.00 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,969 4,969 Term Loan 15.00 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,483 2,483 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) March 31, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Swift Health Systems Inc. (2)(12) Medical Device Term Loan 13.00 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,457 3,457 Term Loan 13.00 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,457 3,457 Term Loan 13.25 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,447 3,447 Term Loan 13.25 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,447 3,447 Total Non-Affiliate Debt Investments — Life Science 309,108 307,749 Non-Affiliate Debt Investments — Sustainability — 25.8% Aerofarms, Inc. (2)(12) Other Sustainability Term Loan 14.75 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,704 3,585 Term Loan 14.75 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,704 3,585 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,383 7,245 Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,383 7,245 Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,383 7,245 Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,912 4,820 Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,912 4,820 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,935 4,935 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,467 2,467 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,932 4,932 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,466 2,466 Term Loan 13.50 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 5,000 4,909 4,909 Term Loan 13.50 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 2,500 2,454 2,454 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,706 3,706 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,720 3,720 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 7,500 7,431 7,431 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,715 3,715 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,715 3,715 Total Non-Affiliate Debt Investments — Sustainability 83,831 82,995 Non-Affiliate Debt Investments — Technology — 83.2% Axiom Space, Inc. (2)(12) Communications Term Loan 13.75 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,459 7,459 Term Loan 13.75 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,459 7,459 Term Loan 13.75 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,459 7,459 Better Place Forests Co. (12)(13) Consumer-related Technologies Term Loan 14.25 % Prime 6.25 % 9.50 % - 1.85 % July 1, 2025 5,000 4,951 3,467 Term Loan 14.25 % Prime 6.25 % 9.50 % - 1.85 % October 1, 2025 2,500 2,474 1,733 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 15.25 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,464 3,464 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 13.50 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,333 2,318 2,318 Term Loan 13.50 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,333 2,318 2,318 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) March 31, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,520 3,520 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,239 1,239 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,717 3,717 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,239 1,239 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,717 3,717 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,239 1,239 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,701 3,701 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,701 3,701 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % April 1, 2028 3,750 3,698 3,698 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 13.00 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,165 1,165 Term Loan 13.00 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 1,748 1,748 Term Loan 11.50 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 11.50 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Interior Define, Inc. (2)(12)(13) Consumer-related Technologies Term Loan 14.50 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 3,246 3,162 — Term Loan 14.50 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 2,963 2,886 — Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 10.50 % Prime 2.50 % 8.00 % - - September 1, 2027 2,598 2,586 2,330 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.75 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 5,000 4,961 4,961 Term Loan 14.75 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,500 2,480 2,480 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,169 5,121 4,883 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,067 2,050 1,955 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,584 2,564 2,446 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 3,101 3,076 2,934 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,584 2,548 2,430 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,584 2,548 2,430 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,169 5,093 4,859 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,584 2,545 2,428 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,355 2,355 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 15.00 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,300 2,277 2,277 Term Loan 15.00 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,300 2,277 2,277 Term Loan 15.00 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 2,900 2,870 2,870 Unagi, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 1,065 1,041 1,041 Term Loan 15.75 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 533 520 520 Term Loan 15.75 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 533 521 521 Liqid, Inc. (2)(12) Networking Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 2,833 2,793 2,793 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 2,833 2,793 2,793 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,417 1,395 1,395 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,417 1,395 1,395 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,417 1,371 1,371 BriteCore Holdings, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,488 2,488 Term Loan 14.50 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,488 2,488 Term Loan 14.50 % Prime 6.75 % 10.00 % - 3.00 % March 1, 2027 2,500 2,467 2,467 Term Loan 14.50 % Prime 6.75 % 10.00 % - 3.00 % March 1, 2027 2,500 2,467 2,467 Decisyon, Inc. (12) Software Term Loan 17.43 % Prime 9.43 % 12.68 % - 50.43 % December 31, 2022 3,284 3,284 2,750 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) March 31, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,500 6,359 6,359 Term Loan 14.50 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,000 5,869 5,869 Term Loan 14.50 % Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,500 2,442 2,442 Engage3, LLC (2)(12) Software Term Loan 14.00 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,680 3,680 Term Loan 14.00 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,720 3,720 Groundspeed Analytics, Inc. (2)(12) Software Term Loan 13.50 % Prime 5.50 % 11.00 % 18.00 % 3.00 % December 1, 2026 5,000 4,802 4,802 Term Loan 13.50 % Prime 5.50 % 11.00 % 18.00 % 3.00 % December 1, 2026 5,000 4,953 4,953 Convertible Note 15.00 % September 10,2024 500 500 500 Kodiak Robotics, Inc. (2)(12) Software Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,843 9,843 Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,843 9,843 Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,921 4,921 Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,921 4,921 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,953 4,953 Term Loan 14.50 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,477 2,477 Lytics, Inc. (2)(12) Software Term Loan 13.75 % Prime 6.00 % 9.25 % - 3.00 % November 1, 2026 2,500 2,411 2,411 Term Loan 13.75 % Prime 6.00 % 12.25 % - 3.00 % December 1, 2026 1,250 1,232 1,232 Term Loan 13.75 % Prime 6.00 % 12.25 % - 3.00 % April 1, 2027 1,000 984 984 Noodle Partners, Inc. (2)(12) Software Term Loan 13.00 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 10,000 9,733 9,733 Term Loan 13.00 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,928 4,928 Term Loan 13.00 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,928 4,928 Reputation Institute, Inc. (2)(12) Software Term Loan 15.00 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 4,833 4,772 4,772 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 13.75 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,940 4,940 Term Loan 13.75 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,940 4,940 Term Loan 13.75 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,875 4,875 Term Loan 13.75 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,940 4,940 Supply Network Visibility Holdings LLC (2)(12) Software Term Loan 14.25 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,208 3,183 3,183 Term Loan 14.25 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,208 3,183 3,183 Term Loan 14.25 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,475 2,475 Term Loan 14.25 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,475 2,475 Total Non-Affiliate Debt Investments — Technology 277,916 267,673 Non-Affiliate Debt Investments — Healthcare information and services — 8.1% Hound Labs inc. (2) (12) Diagnostics Term Loan 14.00 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,388 2,388 Term Loan 14.00 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,476 2,476 Term Loan 14.00 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,951 4,951 Secure Transfusion Services, Inc. (12)(13) Other Healthcare Term Loan 13.75 % Prime 5.75 % 9.00 % - 4.00 % October 1, 2025 4,719 4,658 46 Term Loan 13.75 % Prime 5.75 % 9.00 % - 4.00 % December 31, 2025 2,217 2,182 5 BrightInsight, Inc. (2)(12) Software Term Loan 13.25 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,663 6,663 Term Loan 13.25 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,452 3,452 Term Loan 13.25 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,452 3,452 Term Loan 13.50 % Prime 5.50 % 9.50 % - 3.00 % April 1, 2028 2,750 2,704 2,704 Total Non-Affiliate Debt Investments — Healthcare information and services 32,926 26,137 Total Non- Affiliate Debt Investments 703,781 684,554 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) March 31, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 8.0% Non-Affiliate Warrants — Life Science — 2.1% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,444 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 214 329 Corvium, Inc. (2)(12) Biotechnology Preferred Stock Warrant 661,956 53 — Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 256 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 463,915 126 — Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 47,452 366 — Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 19,671 66 — IMV Inc. (2)(5)(12) Biotechnology Common Stock Warrant 39,774 67 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,076 50 56 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 252,161 141 — Native Microbials, Inc (2)(12) Biotechnology Preferred Stock Warrant 103,679 64 159 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 160 937 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 254,609 401 128 Rocket Pharmaceuticals Corporation (5)(12) Biotechnology Common Stock Warrant 7,051 17 2 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 28 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 9 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 66 1,196 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 27,330 48 31 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 86 1,862 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 206 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 775,000 144 173 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 221 221 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,375,727 153 148 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 72 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 51 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) March 31, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 379 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 98 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 15 Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 19,662 40 45 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 605,313 98 120 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 81 Total Non-Affiliate Warrants — Life Science 4,158 6,603 Non-Affiliate Warrants — Sustainability — 0.2% Aerofarms, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 201,537 61 72 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,359 39 53 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Common Stock Warrant 204,195 490 1 Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 354 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 34,604 118 259 Total Non-Affiliate Warrants — Sustainability 922 739 Non-Affiliate Warrants — Technology — 5.1% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 46 64 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,251 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 91 170 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 64 Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Better Place Forests Co. (12) Consumer-related Technologies Preferred Stock Warrant 2,672 26 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,057 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 17,605 22 — Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 30 124 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 33,742 70 237 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,942 2,674 MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 143 29 36 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 1,261,253 197 17 Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,600 104 104 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 427 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 532 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 111 Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 42 CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 903 Silk, Inc. (2)(12) Data Storage Preferred and Common Stock Warrant 442,110 234 399 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 — Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 352 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 1,231 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 237 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,808 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrants 6,081 57 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 77,828 21 67 Decisyon, Inc. (12) Software Common Stock Warrant 82,967 46 — Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 196 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 — Groundspeed Analytics, Inc. (2)(12) Software Preferred Stock Warrant 86,300 7 1 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 275 287 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 35 40 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 71,305 19 53 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 85,543 43 46 Noodle Partners, Inc. (2)(12) Software Preferred Stock Warrant 84,037 116 116 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 61 46 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 44 97 Riv Data Corp. (2)(12) Software Preferred Stock Warrant 321,428 12 296 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 135 Supply Network Visibility Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 140 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 11 Total Non-Affiliate Warrants — Technology 9,231 16,371 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) March 31, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 159,893 47 53 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 102 1,363 Secure Transfusion Services, Inc. (12) Other Healthcare Preferred Stock Warrant 77,690 48 — BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 85,066 167 175 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 60 354 Total Non-Affiliate Warrants — Healthcare information and services 424 1,945 Total Non-Affiliate Warrants 14,735 25,658 Non-Affiliate Other Investments — 0.4% Lumithera, Inc. (12) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — 200 Total Non-Affiliate Other Investments 1,200 1,300 Non-Affiliate Equity — 0.9% Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (12) Biotechnology Common Stock 32,831 356 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 25 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 9 83 Lumithera, Inc. (12) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (12) Other Sustainability Preferred Stock 22,313 8 27 Branded Online, Inc. (2)(5) Software Common Stock 5,398 1,075 14 Decisyon, Inc. (12) Software Preferred and Common Stock 72,638,663 229 — Lotame, Inc. (12) Software Preferred Stock 66,127 5 193 Axiom Space, Inc. (12) Technology Preferred Stock 1,810 261 306 Total Non-Affiliate Equity 4,446 2,954 Total Non-Affiliate Portfolio Investment Assets $ 724,162 $ 714,466 Non-controlled Affiliate Investments — 0.3% Non-controlled Affiliate Equity — Life Science — 0.3% Cadrenal Therapeutics, Inc. (5) Biotechnology Common Stock 600,000 — 846 Total Non-Controlled Affiliate Equity $ — 846 Total Non-Controlled Affiliate Portfolio Investment Assets $ — 846 Total Portfolio Investment Assets — 222.4% $ 724,162 $ 715,312 ( 1 All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States. ( 2 Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”, together with the Key Facility, the "Credit Facilities") with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”), the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $160.0 million securitization of secured loans the Company completed on August 13, 2019 ( “2019 November 9, 2022 ( “2022 ( 3 All non-affiliate investments are investments in which the Company owns less than 5% 5% not 25% 25% ( 4 All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not one March 31, 2023 ( 5 Portfolio company is a public company. ( 6 For debt investments, represents principal balance less unearned income. ( 7 Warrants, Equity and Other Investments are non-income producing. ( 8 Value as a percent of net assets. ( 9 As of March 31, 2023 1940 may not 70% ( 10 ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may not ( 11 Debt investment has a payment-in-kind (“PIK”) feature. ( 12 The fair value of the investment was valued using significant unobservable inputs. ( 13 Debt investment is on non-accrual status as of March 31, 2023 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 226.1% Non-Affiliate Debt Investments — 215.5% Non-Affiliate Debt Investments — Life Science — 99.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.7

Note 1 - Organization

Note 1 - Organization	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 1940 1986, not On October 28, 2010, Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, not The Company formed Horizon Funding 2019‑1 “2019‑1 May 2, 2019 2019‑1 May 15, 2019 “2019‑1 2019‑1 “2019‑1 2019‑1 2019‑1 2019 Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, not April 21, 2020, The Company formed Horizon Funding 2022‑1 “2022‑1 September 30, 2022 2022‑1 October 18, 2022 ( “2022‑1 2022‑1 “2022‑1 2022‑1 2022‑1 2022 The Company has also established an additional wholly owned subsidiary, which is structured as a Delaware limited liability company, to hold the assets of a portfolio company acquired in connection with foreclosure or bankruptcy, which is a separate legal entity from the Company. The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q 6 10 X X” 1933, not may December 31, 2022 Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments. Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment. Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may March 31, 2023 three December 31, 2022 three three March 31, 2023 2022, not The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three March 31, 2023 2022 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 three March 31, 2023 2022 Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no Depending on the level of taxable income earned in a tax year, the Company may three March 31, 2023 2022 The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not March 31, 2023 December 31, 2022 2021, 2020 2019 Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may Stockholders Equity On August 2, 2021, “2021 2021 may may 415 During the three March 31, 2023 2021 During the three March 31, 2022 2021 On March 14, 2022, The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of March 31, 2023 2021 Stock Repurchase Program On April 28, 2023, may, not 10b‑18 1934, 1940 June 30, 2024 $5.0 three March 31, 2023 2022 not March 31, 2023 Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 3. Investment Management Agreement At a special meeting of the stockholders on October 30, 2018, March 7, 2019. October 28, 2010 July 1, 2014. October 28, 2022, On February 23, 2023, one hundred May 25, 2023 not April 6, 2023, http://www.sec.gov The Advisor’s services under the Investment Management Agreement are not not two The base management fee was and will be calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 $250 The base management fee payable at March 31, 2023 December 31, 2022 three March 31, 2023 2022 The incentive fee has two The first zero not no 1.75%, 2.1875% 20.00% not Pre-Incentive Fee Net Investment Income does not may 2.00% three The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three 11 may 20.00% zero not three The second 20.00% not The performance based incentive fee expense was $3.0 million and $1.4 million for the three March 31, 2023 2022 three March 31, 2023, may three March 31, 2023 not three March 31, 2022. March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 one Administration Agreement The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million for the three March 31, 2023 2022

Note 4 - Investments

Note 4 - Investments	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Investment Holdings [Text Block]	Note 4. The following table shows the Company’s investments as of March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 703,781 $ 684,554 $ 701,074 $ 686,458 Warrants 14,735 25,658 14,790 29,712 Other 1,200 1,300 1,200 1,300 Equity 4,446 3,800 4,184 2,556 Total investments $ 724,162 $ 715,312 $ 721,248 $ 720,026 The following table shows the Company’s investments by industry sector as of March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 187,970 $ 186,981 $ 193,372 $ 195,006 Medical Device 129,102 131,823 132,803 135,960 Technology Communications 22,913 26,168 22,892 26,176 Consumer-Related 107,802 99,140 121,961 114,050 Data Storage 476 1,302 476 1,316 Internet and Media 329 1,583 329 1,159 Networking 10,111 9,984 11,831 11,710 Power Management 1,585 2,808 1,585 2,610 Semiconductors 57 — 56 — Software 145,706 143,680 120,157 118,716 Sustainability Energy Efficiency 8 27 8 27 Other Sustainability 84,753 83,734 84,633 85,524 Healthcare Information and Services Diagnostics 9,862 9,868 9,851 9,858 Other 6,990 1,414 7,559 3,870 Software 16,498 16,800 13,735 14,044 Total investments $ 724,162 $ 715,312 $ 721,248 $ 720,026

Note 5 - Transactions With Affi

Note 5 - Transactions With Affiliated Companies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	Note 5. A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% not 25% Transactions related to investments in non-controlled affiliated companies for the three March 31, 2023 Three months ended March 31, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized March 31, Interest Company 2022 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Cadrenal Therapeutics, Inc. $ — $ — $ — $ — $ — $ 846 $ — $ 846 $ — Total non-controlled affiliates $ — $ — $ — $ — $ — $ 846 $ — $ 846 $ — For the three March 31, 2022, A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% For the three March 31, 2023, Transactions related to investments in controlled affiliated companies for the three March 31, 2022 Three months ended March 31, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized March 31, Dividend Company 2021 Purchases Sales fair value declared gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (50 ) — — 50 — — — Total controlled affiliates $ — $ — $ (50 ) $ — $ — $ 50 $ — $ — $ —

Note 6 - Fair Value

Note 6 - Fair Value	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 6. Prior to July 30, 2022, 2a 5 1940 July 29, 2022, twelve The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no not may not Fair value measurements focus on exit prices in an orderly transaction (that is, not may The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement three Level 1 Quoted prices in active markets for identical assets and liabilities. Level 2 Observable inputs other than Level 1 not Level 3 Unobservable inputs that are supported by little or no 3 Due to the inherent uncertainty of determining the fair value of investments that do not may may may may Cash and interest receivable: not 1 Money market funds: 2 Debt investments: 3 Under certain circumstances, the Company may Warrant investments: ● Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. ● Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven ● The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. ● Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. ● Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may Under certain circumstances the Company may may The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 3 Equity investments: third may 3 1 Other investments: 3 The following tables detail the investments that are carried at fair value and measured at fair value on a recurring basis as of March 31, 2023 December 31, 2022 March 31, 2023 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 684,554 $ 684,554 Warrant investments — 1,020 24,638 25,658 Other investments — — 1,300 1,300 Equity investments 885 — 2,915 3,800 Total investments $ 885 $ 1,020 $ 713,407 $ 715,312 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026 The following tables provide a summary of quantitative information about the Company’s Level 3 March 31, 2023 December 31, 2022 may The following table is not 3 March 31, 2023 March 31, 2023 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 644,854 Discounted Expected Future Cash Flows Hypothetical Market Yield 11% – 20% 14 % 39,700 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 100% 43 % Warrant investments 24,638 Black-Scholes Valuation Model Price Per Share 0.100 –1,89999 $ 62.82 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,915 Last Equity Financing Price Per Share $1.00– $215.03 $ 40.27 Total Level 3 investments $ 713,407 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 The following table is not 3 December 31, 2022 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1.89999 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 Borrowings: 2 2026 7 March 31, 2023 2026 1 2027 7 March 31, 2023 2027 1 March 31, 2023 2019 3 March 31, 2023 2022 3 not Off-balance-sheet instruments: 3 The following table shows a reconciliation of the beginning and ending balances for Level 3 three March 31, 2023 Three months ended March 31, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Purchase of investments 46,998 — 10 — 47,008 Warrants received and classified as Level 3 — 141 — — 141 Principal payments received on investments (39,756 ) — — — (39,756 ) Payment-in-kind interest on investments 1,204 — — — 1,204 Proceeds from sale of investments (6,508 ) (12 ) — — (6,520 ) Net realized gain (loss) on investments 7 (141 ) — — (134 ) Unrealized (depreciation) appreciation included in earnings (4,566 ) (1,490 ) 189 — (5,867 ) Transfer out of debt investments (295 ) (5 ) 300 — — Other 1,012 — — — 1,012 Level 3 assets, end of period $ 684,554 $ 24,638 $ 2,915 $ 1,300 $ 713,407 During the three March 31, 2023 3. The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 March 31, 2023 The following table shows a reconciliation of the beginning and ending balances for Level 3 three March 31, 2022 Three months ended March 31, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 94,485 — — — 94,485 Warrants received and classified as Level 3 — 808 — — 808 Principal payments received on investments (14,095 ) — — (50 ) (14,145 ) Proceeds from sale of investments (21,250 ) (30 ) — — (21,280 ) Net realized gain on investments — 30 — — 30 Unrealized (depreciation) appreciation included in earnings (3,170 ) 1,000 — 50 (2,120 ) Other (1,093 ) — — — (1,093 ) Level 3 assets, end of period $ 492,194 $ 21,645 $ 203 $ 200 $ 514,242 During the three March 31, 2022 3. The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 March 31, 2022 The Company discloses fair value information about financial instruments, whether or not not The fair value amounts have been measured as of the reporting date and have not may As of March 31, 2023 December 31, 2022 Market risk The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may

Note 7 - Borrowings

Note 7 - Borrowings	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7. The following table shows the Company’s borrowings as of March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 125,000 $ 15,000 $ 110,000 $ 125,000 $ 5,000 $ 120,000 NYL Facility 200,000 176,750 23,250 200,000 176,750 23,250 2019 Asset-Backed Notes 37,791 37,791 — 42,573 42,573 — 2022 Asset-Backed Notes 100,000 100,000 — 100,000 100,000 — 2027 Notes 57,500 57,500 — 57,500 57,500 — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 577,791 444,541 133,250 582,573 439,323 143,250 Unamortized debt issuance costs attributable to term borrowings — (4,896 ) — — (5,245 ) — Total borrowings outstanding, net $ 577,791 $ 439,645 $ 133,250 $ 582,573 $ 434,078 $ 143,250 As of March 31, 2023 1940 March 31, 2023 Credit Facilities Key Facility The Company entered into the Key Facility with Key effective November 4, 2013. June 22, 2021, may June 22, 2024. June 22, 2026. March 31, 2023 December 31, 2022 three March 31, 2023 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 NYL Facility On April 21, 2020, June 1, 2018, three On February 25, 2022, June 2023 June 2028. $100.0 three There were $176.8 million in advances made by the NYL Noteholders as of March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may March 31, 2023 December 31, 2022 Securitizations 2019 On August 13, 2019, 2019 2019 no August 13, 2019. The 2019 2019‑1 August 13, 2019, 2019 2019 July 15, 2021 September 15, 2027. As of March 31, 2023 December 31, 2022 2019 Under the terms of the 2019 2019 may 2019 March 31, 2023 December 31, 2022 2022 On November 9, 2022, 2022 2022 no November 9, 2022. The 2022 2022‑1 November 9, 2022, 2022 2022 November 15, 2024 November 15, 2030. As of March 31, 2023 December 31, 2022 2022 Under the terms of the 2022 2022 may 2022 March 31, 2023 December 31, 2022 Unsecured Notes 2026 On March 30, 2021, 2026 “2026 2026 2026 March 30, 2026 may March 30, 2023 2026 4.875% March 30, June 30, September 30 December 30 2026 2026 March 31, 2023 2026 2026 2027 On June 15, 2022, 2027 July 11, 2022, 30 “2027 2027 June 15, 2027 may June 15, 2024 2027 6.25% March 30, June 30, September 30 December 30 September 30, 2022. 2027 2027 March 31, 2023 2027 2027

Note 8 - Financial Instruments

Note 8 - Financial Instruments With Off-balance-sheet Risk	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	Note 8. In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate. The balance of unfunded commitments to extend credit was $166.2 million and $190.0 million as of March 31, 2023 December 31, 2022 may not The following table provides the Company’s unfunded commitments by portfolio company as of March 31, 2023 March 31, 2023 December 31, 2022 Fair Value of Fair Value of Unfunded Unfunded Principal Commitment Principal Commitment Balance Liability Balance Liability (In thousands) (In thousands) BrightInsight, Inc. $ 18,250 $ 241 $ 21,000 $ 278 Britecore Holdings, Inc. — — 5,000 66 Castle Creek Biosciences 4,000 72 4,000 72 Corinth Medtech, Inc. 200 — — — Divergent Technologies, Inc. 18,750 197 22,500 236 Engage3, LLC 8,000 40 8,000 40 Groundspeed Analytics, Inc. 15,500 150 15,000 150 Hound Labs, Inc. 7,500 88 7,500 88 KSQ Therapeutics, Inc. 10,000 100 10,000 100 Lytics, Inc. 4,000 52 5,000 65 Native Microbials, Inc. — — 7,500 72 Noodle Partners, Inc. 10,000 123 — — Optoro, Inc. 15,000 38 15,000 38 PDS Biotechnology Corporation 10,000 158 10,000 158 Robin Healthcare, Inc. 5,000 50 10,000 100 Scientia Vascular, Inc. 10,000 110 10,000 110 Slingshot Aerospace, Inc. 5,000 63 5,000 64 Swift Health Systems Inc. 18,500 — 25,500 105 Temperpack Technologies, Inc. 6,500 14 9,000 19 Total $ 166,200 $ 1,496 $ 190,000 $ 1,761 The table above also provides the fair value of the Company’s unfunded commitment liability as of March 31, 2023 December 31, 2022,

Note 9 - Concentrations of Cred

Note 9 - Concentrations of Credit Risk	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 9. The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may may The Company’s largest debt investments may five March 31, 2023 December 31, 2022 No 10% March 31, 2023 December 31, 2022 five three March 31, 2023 2022

Note 10 - Distributions

Note 10 - Distributions	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 10. The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the three March 31, 2023 December 31, 2022 DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Three Months Ended March 31, 2023 2/23/2023 5/18/23 6/14/23 $ 0.11 $ — — $ — 2/23/2023 4/18/23 5/16/23 0.11 — — — 2/23/2023 3/17/23 4/14/23 0.11 3,035 6,894 81 $ 0.33 $ 3,035 6,894 $ 81 Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ 3,040 6,764 $ 75 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 32,659 61,859 $ 754 On April 28, 2023, Monthly distributions Ex-Dividend Date Record Date Payment Date Distributions Declared June 15, 2023 June 16, 2023 July 14, 2023 $ 0.11 July 17, 2023 July 18, 2023 August 15, 2023 $ 0.11 August 16, 2023 August 17, 2023 September 15, 2023 $ 0.11 After paying distributions of $0.33 per share and earning net investment income of $0.46 per share for the quarter, the Company’s undistributed spillover income as of March 31, 2023 not

Note 11 - Financial Highlights

Note 11 - Financial Highlights	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Investment Company, Financial Highlights [Text Block]	Note 11. The following table shows financial highlights for the Company: Three months ended March 31, 2023 2022 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.47 $ 11.56 Net investment income 0.46 0.26 Realized loss (0.01 ) — Unrealized depreciation on investments (0.26 ) (0.10 ) Net increase in net assets resulting from operations 0.19 0.16 Distributions declared (1) (0.33 ) (0.30 ) From net investment income (0.33 ) (0.30 ) From net realized gain on investments — — Return of capital — — Other (2) 0.01 0.26 Net asset value at end of period $ 11.34 $ 11.68 Per share market value, beginning of period $ 11.60 $ 15.92 Per share market value, end of period $ 11.28 $ 13.90 Total return based on a market value (3) 0.1 % (10.8 )% Shares outstanding at end of period 28,377,357 23,977,137 Ratios to average net assets: Expenses without incentive value (4) 14.8 % 10.6 % Incentive fees (4) 3.7 % 2.2 % Net expenses (4) 18.5 % 12.8 % Net investment income with incentive fees (4) 16.3 % 8.7 % Net assets at the end of the period $ 321,683 $ 279,989 Average net asset value $ 320,066 $ 262,662 Average debt per share $ 15.61 $ 12.21 Portfolio turnover ratio 4.2 % (5) 2.6 % (5) ( 1 Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may ( 2 Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share. ( 3 The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price. ( 4 Annualized. ( 5 Calculated by dividing the lesser of purchases or the sum of ( 1 2

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. In April 2023 , 2021 IMV Inc. (“IMV”) (NASDAQ: IMV; TSX: IMV), announced on May 1, 2023 1985, 36 15

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not
Use of Estimates, Policy [Policy Text Block]	Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair Value Measurement, Policy [Policy Text Block]	Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6
Segment Reporting, Policy [Policy Text Block]	Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
Investment, Policy [Policy Text Block]	Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may March 31, 2023 three December 31, 2022 three three March 31, 2023 2022, not The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three March 31, 2023 2022 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not
Debt, Policy [Policy Text Block]	Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 three March 31, 2023 2022
Income Tax, Policy [Policy Text Block]	Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no Depending on the level of taxable income earned in a tax year, the Company may three March 31, 2023 2022 The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not March 31, 2023 December 31, 2022 2021, 2020 2019
Distributions [Policy Text Block]	Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may
Stockholders' Equity, Policy [Policy Text Block]	Stockholders Equity On August 2, 2021, “2021 2021 may may 415 During the three March 31, 2023 2021 During the three March 31, 2022 2021 On March 14, 2022, The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of March 31, 2023 2021
Stock Repurchase Program [Policy Text Block]	Stock Repurchase Program On April 28, 2023, may, not 10b‑18 1934, 1940 June 30, 2024 $5.0 three March 31, 2023 2022 not March 31, 2023
Transfers and Servicing of Financial Assets, Policy [Policy Text Block]	Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03

Consolidated Schedule of Inve_2

Consolidated Schedule of Investments (Unaudited) (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Investment [Table Text Block]	Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 222.1% Non-Affiliate Debt Investments — 212.8% Non-Affiliate Debt Investments — Life Science — 95.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,913 $ 2,860 $ 2,779 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,832 2,752 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,416 1,375 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,829 2,749 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,829 2,749 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,412 1,370 Term Loan 14.25 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,412 1,370 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,895 4,895 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,967 4,967 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,977 2,977 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,967 4,967 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,970 4,970 Term Loan 12.88 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,980 2,980 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.57 % Libor 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,965 1,965 Term Loan 12.57 % Libor 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,966 1,966 Term Loan 12.57 % Libor 4.72 % 9.75 % - 5.00 % November 1, 2025 5,000 4,930 4,930 Term Loan 12.57 % Libor 4.72 % 9.75 % - 5.00 % May 1, 2026 5,000 4,921 4,921 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 10,000 9,880 9,880 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 15,000 14,819 14,819 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 6,000 5,928 5,928 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 6,000 5,928 5,928 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,000 3,952 3,952 Term Loan 12.25 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,000 3,952 3,952 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 4,500 4,371 4,352 Term Loan 13.75 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,250 2,187 2,177 IMV Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,000 4,951 4,759 Term Loan 13.75 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,476 2,380 Term Loan 13.75 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,953 4,761 Term Loan 13.75 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,953 4,761 KSQ Therapeutics, Inc. (2) (12) Biotechnology Term Loan 12.75 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,082 6,082 Term Loan 12.75 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,182 6,182 Native Microbials, Inc (2) (12) Biotechnology Term Loan 13.25 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,707 3,707 Term Loan 13.25 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,472 2,472 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,714 9,714 Term Loan 13.75 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,702 3,702 Term Loan 13.75 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,702 3,702 Provivi, Inc. (2)(12) Biotechnology Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,667 4,606 4,606 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,667 4,606 4,606 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,287 2,287 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,287 2,287 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Term Loan 13.17 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 13.50 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 5,000 4,922 4,922 Term Loan 13.50 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,500 2,461 2,461 Aerobiotix, LLC (2)(12) Medical Device Term Loan 14.25 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,467 2,361 Term Loan 14.25 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,467 2,361 Ceribell, Inc. (2)(12) Medical Device Term Loan 11.25 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,977 4,977 Term Loan 11.25 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,977 4,977 Term Loan 11.25 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,481 2,481 Term Loan 11.25 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,481 2,481 Cognoa, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 5,000 4,940 4,940 Term Loan 13.50 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,500 2,470 2,470 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 12.67 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,904 3,904 Term Loan 12.67 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,904 3,904 Corinth Medtech, Inc. (2)(12) Medical Device Term Loan 13.00 % (11) Prime 5.25 % 8.50 % - 20.00 % June 30, 2023 2,528 2,528 2,528 Term Loan 13.00 % (11) Prime 5.25 % 8.50 % - 20.00 % June 30, 2023 2,528 2,528 2,528 Term Loan 13.00 % (11) Prime 5.25 % 8.50 % - 50.00 % June 30, 2023 200 200 200 CSA Medical, Inc. (2)(12) Medical Device Term Loan 12.87 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 1,250 1,239 1,239 Term Loan 12.87 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 83 83 83 Term Loan 12.87 % Libor 8.20 % 10.00 % - 5.00 % March 1, 2024 1,600 1,587 1,587 InfoBionic, Inc. (2)(12) Medical Device Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 2,771 2,715 2,715 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 977 977 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,946 4,946 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,946 4,946 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,940 4,940 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,941 4,941 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,920 4,920 Term Loan 12.75 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,920 4,920 Robin Healthcare, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,413 3,413 Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,463 3,463 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 12.50 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,601 3,601 Term Loan 12.50 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,710 3,710 Sonex Health, Inc. (2)(12) Medical Device Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % April 1, 2026 2,500 2,459 2,459 Term Loan 14.25 % Prime 6.50 % 9.75 % - 8.00 % May 1, 2026 2,500 2,458 2,458 Spineology, Inc. (2)(12) Medical Device Term Loan 15.00 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,969 4,969 Term Loan 15.00 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,483 2,483 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Swift Health Systems Inc. (2)(12) Medical Device Term Loan 13.00 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,457 3,457 Term Loan 13.00 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,457 3,457 Term Loan 13.25 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,447 3,447 Term Loan 13.25 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,447 3,447 Total Non-Affiliate Debt Investments — Life Science 309,108 307,749 Non-Affiliate Debt Investments — Sustainability — 25.8% Aerofarms, Inc. (2)(12) Other Sustainability Term Loan 14.75 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,704 3,585 Term Loan 14.75 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,704 3,585 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,383 7,245 Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,383 7,245 Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,383 7,245 Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,912 4,820 Term Loan 15.00 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,912 4,820 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,935 4,935 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,467 2,467 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,932 4,932 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,466 2,466 Term Loan 13.50 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 5,000 4,909 4,909 Term Loan 13.50 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 2,500 2,454 2,454 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,706 3,706 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,720 3,720 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 7,500 7,431 7,431 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,715 3,715 Term Loan 14.75 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,715 3,715 Total Non-Affiliate Debt Investments — Sustainability 83,831 82,995 Non-Affiliate Debt Investments — Technology — 83.2% Axiom Space, Inc. (2)(12) Communications Term Loan 13.75 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,459 7,459 Term Loan 13.75 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,459 7,459 Term Loan 13.75 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,459 7,459 Better Place Forests Co. (12)(13) Consumer-related Technologies Term Loan 14.25 % Prime 6.25 % 9.50 % - 1.85 % July 1, 2025 5,000 4,951 3,467 Term Loan 14.25 % Prime 6.25 % 9.50 % - 1.85 % October 1, 2025 2,500 2,474 1,733 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 15.25 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,464 3,464 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 13.50 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,333 2,318 2,318 Term Loan 13.50 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,333 2,318 2,318 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,520 3,520 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,239 1,239 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,717 3,717 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,239 1,239 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,717 3,717 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,239 1,239 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,701 3,701 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,701 3,701 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % April 1, 2028 3,750 3,698 3,698 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 13.00 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,165 1,165 Term Loan 13.00 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 1,748 1,748 Term Loan 11.50 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 11.50 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Interior Define, Inc. (2)(12)(13) Consumer-related Technologies Term Loan 14.50 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 3,246 3,162 — Term Loan 14.50 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 2,963 2,886 — Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 10.50 % Prime 2.50 % 8.00 % - - September 1, 2027 2,598 2,586 2,330 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.75 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 5,000 4,961 4,961 Term Loan 14.75 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,500 2,480 2,480 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,169 5,121 4,883 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,067 2,050 1,955 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,584 2,564 2,446 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 3,101 3,076 2,934 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,584 2,548 2,430 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,584 2,548 2,430 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,169 5,093 4,859 Term Loan 13.50 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,584 2,545 2,428 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,355 2,355 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 15.00 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,300 2,277 2,277 Term Loan 15.00 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,300 2,277 2,277 Term Loan 15.00 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 2,900 2,870 2,870 Unagi, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 1,065 1,041 1,041 Term Loan 15.75 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 533 520 520 Term Loan 15.75 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 533 521 521 Liqid, Inc. (2)(12) Networking Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 2,833 2,793 2,793 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 2,833 2,793 2,793 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,417 1,395 1,395 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,417 1,395 1,395 Term Loan 14.00 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,417 1,371 1,371 BriteCore Holdings, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,488 2,488 Term Loan 14.50 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,488 2,488 Term Loan 14.50 % Prime 6.75 % 10.00 % - 3.00 % March 1, 2027 2,500 2,467 2,467 Term Loan 14.50 % Prime 6.75 % 10.00 % - 3.00 % March 1, 2027 2,500 2,467 2,467 Decisyon, Inc. (12) Software Term Loan 17.43 % Prime 9.43 % 12.68 % - 50.43 % December 31, 2022 3,284 3,284 2,750 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,500 6,359 6,359 Term Loan 14.50 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,000 5,869 5,869 Term Loan 14.50 % Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,500 2,442 2,442 Engage3, LLC (2)(12) Software Term Loan 14.00 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,680 3,680 Term Loan 14.00 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,720 3,720 Groundspeed Analytics, Inc. (2)(12) Software Term Loan 13.50 % Prime 5.50 % 11.00 % 18.00 % 3.00 % December 1, 2026 5,000 4,802 4,802 Term Loan 13.50 % Prime 5.50 % 11.00 % 18.00 % 3.00 % December 1, 2026 5,000 4,953 4,953 Convertible Note 15.00 % September 10,2024 500 500 500 Kodiak Robotics, Inc. (2)(12) Software Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,843 9,843 Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,843 9,843 Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,921 4,921 Term Loan 13.50 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,921 4,921 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,953 4,953 Term Loan 14.50 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,477 2,477 Lytics, Inc. (2)(12) Software Term Loan 13.75 % Prime 6.00 % 9.25 % - 3.00 % November 1, 2026 2,500 2,411 2,411 Term Loan 13.75 % Prime 6.00 % 12.25 % - 3.00 % December 1, 2026 1,250 1,232 1,232 Term Loan 13.75 % Prime 6.00 % 12.25 % - 3.00 % April 1, 2027 1,000 984 984 Noodle Partners, Inc. (2)(12) Software Term Loan 13.00 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 10,000 9,733 9,733 Term Loan 13.00 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,928 4,928 Term Loan 13.00 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,928 4,928 Reputation Institute, Inc. (2)(12) Software Term Loan 15.00 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 4,833 4,772 4,772 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 13.75 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,940 4,940 Term Loan 13.75 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,940 4,940 Term Loan 13.75 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,875 4,875 Term Loan 13.75 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,940 4,940 Supply Network Visibility Holdings LLC (2)(12) Software Term Loan 14.25 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,208 3,183 3,183 Term Loan 14.25 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,208 3,183 3,183 Term Loan 14.25 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,475 2,475 Term Loan 14.25 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,475 2,475 Total Non-Affiliate Debt Investments — Technology 277,916 267,673 Non-Affiliate Debt Investments — Healthcare information and services — 8.1% Hound Labs inc. (2) (12) Diagnostics Term Loan 14.00 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,388 2,388 Term Loan 14.00 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,476 2,476 Term Loan 14.00 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,951 4,951 Secure Transfusion Services, Inc. (12)(13) Other Healthcare Term Loan 13.75 % Prime 5.75 % 9.00 % - 4.00 % October 1, 2025 4,719 4,658 46 Term Loan 13.75 % Prime 5.75 % 9.00 % - 4.00 % December 31, 2025 2,217 2,182 5 BrightInsight, Inc. (2)(12) Software Term Loan 13.25 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,663 6,663 Term Loan 13.25 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,452 3,452 Term Loan 13.25 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,452 3,452 Term Loan 13.50 % Prime 5.50 % 9.50 % - 3.00 % April 1, 2028 2,750 2,704 2,704 Total Non-Affiliate Debt Investments — Healthcare information and services 32,926 26,137 Total Non- Affiliate Debt Investments 703,781 684,554 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 8.0% Non-Affiliate Warrants — Life Science — 2.1% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,444 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 214 329 Corvium, Inc. (2)(12) Biotechnology Preferred Stock Warrant 661,956 53 — Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 256 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 463,915 126 — Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 47,452 366 — Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 19,671 66 — IMV Inc. (2)(5)(12) Biotechnology Common Stock Warrant 39,774 67 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,076 50 56 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 252,161 141 — Native Microbials, Inc (2)(12) Biotechnology Preferred Stock Warrant 103,679 64 159 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 160 937 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 254,609 401 128 Rocket Pharmaceuticals Corporation (5)(12) Biotechnology Common Stock Warrant 7,051 17 2 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 28 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 9 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 66 1,196 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 27,330 48 31 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 86 1,862 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 206 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 775,000 144 173 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 221 221 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,375,727 153 148 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 72 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 51 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 379 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 98 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 15 Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 19,662 40 45 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 605,313 98 120 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 81 Total Non-Affiliate Warrants — Life Science 4,158 6,603 Non-Affiliate Warrants — Sustainability — 0.2% Aerofarms, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 201,537 61 72 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,359 39 53 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Common Stock Warrant 204,195 490 1 Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 354 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 34,604 118 259 Total Non-Affiliate Warrants — Sustainability 922 739 Non-Affiliate Warrants — Technology — 5.1% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 46 64 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,251 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 91 170 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 64 Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Better Place Forests Co. (12) Consumer-related Technologies Preferred Stock Warrant 2,672 26 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,057 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 17,605 22 — Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 30 124 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 33,742 70 237 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,942 2,674 MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 143 29 36 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 1,261,253 197 17 Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,600 104 104 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 427 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 532 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 111 Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 42 CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 903 Silk, Inc. (2)(12) Data Storage Preferred and Common Stock Warrant 442,110 234 399 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 — Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 352 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 1,231 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 237 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,808 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrants 6,081 57 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 77,828 21 67 Decisyon, Inc. (12) Software Common Stock Warrant 82,967 46 — Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 196 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 — Groundspeed Analytics, Inc. (2)(12) Software Preferred Stock Warrant 86,300 7 1 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 275 287 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 35 40 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 71,305 19 53 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 85,543 43 46 Noodle Partners, Inc. (2)(12) Software Preferred Stock Warrant 84,037 116 116 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 61 46 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 44 97 Riv Data Corp. (2)(12) Software Preferred Stock Warrant 321,428 12 296 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 135 Supply Network Visibility Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 140 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 11 Total Non-Affiliate Warrants — Technology 9,231 16,371 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 159,893 47 53 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 102 1,363 Secure Transfusion Services, Inc. (12) Other Healthcare Preferred Stock Warrant 77,690 48 — BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 85,066 167 175 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 60 354 Total Non-Affiliate Warrants — Healthcare information and services 424 1,945 Total Non-Affiliate Warrants 14,735 25,658 Non-Affiliate Other Investments — 0.4% Lumithera, Inc. (12) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — 200 Total Non-Affiliate Other Investments 1,200 1,300 Non-Affiliate Equity — 0.9% Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (12) Biotechnology Common Stock 32,831 356 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 25 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 9 83 Lumithera, Inc. (12) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (12) Other Sustainability Preferred Stock 22,313 8 27 Branded Online, Inc. (2)(5) Software Common Stock 5,398 1,075 14 Decisyon, Inc. (12) Software Preferred and Common Stock 72,638,663 229 — Lotame, Inc. (12) Software Preferred Stock 66,127 5 193 Axiom Space, Inc. (12) Technology Preferred Stock 1,810 261 306 Total Non-Affiliate Equity 4,446 2,954 Total Non-Affiliate Portfolio Investment Assets $ 724,162 $ 714,466 Non-controlled Affiliate Investments — 0.3% Non-controlled Affiliate Equity — Life Science — 0.3% Cadrenal Therapeutics, Inc. (5) Biotechnology Common Stock 600,000 — 846 Total Non-Controlled Affiliate Equity $ — 846 Total Non-Controlled Affiliate Portfolio Investment Assets $ — 846 Total Portfolio Investment Assets — 222.4% $ 724,162 $ 715,312 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 226.1% Non-Affiliate Debt Investments — 215.5% Non-Affiliate Debt Investments — Life Science — 99.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,885 $ 2,853 $ 2,777 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,823 2,750 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,411 1,374 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,891 4,891 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,962 1,962 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,963 1,963 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,923 4,923 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % May 1, 2026 5,000 4,912 4,912 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 10,000 9,872 9,872 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 15,000 14,808 14,808 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 6,000 5,923 5,923 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 6,000 5,923 5,923 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 4,000 3,949 3,949 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 4,000 3,949 3,949 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,476 2,476 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,473 2,473 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 5,000 4,857 4,857 Term Loan 13.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,500 2,430 2,430 IMV Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,000 4,946 4,946 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,473 2,473 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,947 4,947 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,947 4,947 KSQ Therapeutics, Inc. (2) (12) Biotechnology Term Loan 12.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,077 6,077 Term Loan 12.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,177 6,177 Native Microbials, Inc (2) (12) Biotechnology Term Loan 12.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,630 3,630 Term Loan 12.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,469 2,469 PDS Biotechnology Corporation (2)(5)(12) B

Note 4 - Investments (Tables)

Note 4 - Investments (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Investment Holdings, Schedule of Investments [Table Text Block]	March 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 703,781 $ 684,554 $ 701,074 $ 686,458 Warrants 14,735 25,658 14,790 29,712 Other 1,200 1,300 1,200 1,300 Equity 4,446 3,800 4,184 2,556 Total investments $ 724,162 $ 715,312 $ 721,248 $ 720,026 March 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 187,970 $ 186,981 $ 193,372 $ 195,006 Medical Device 129,102 131,823 132,803 135,960 Technology Communications 22,913 26,168 22,892 26,176 Consumer-Related 107,802 99,140 121,961 114,050 Data Storage 476 1,302 476 1,316 Internet and Media 329 1,583 329 1,159 Networking 10,111 9,984 11,831 11,710 Power Management 1,585 2,808 1,585 2,610 Semiconductors 57 — 56 — Software 145,706 143,680 120,157 118,716 Sustainability Energy Efficiency 8 27 8 27 Other Sustainability 84,753 83,734 84,633 85,524 Healthcare Information and Services Diagnostics 9,862 9,868 9,851 9,858 Other 6,990 1,414 7,559 3,870 Software 16,498 16,800 13,735 14,044 Total investments $ 724,162 $ 715,312 $ 721,248 $ 720,026

Note 5 - Transactions With Af_2

Note 5 - Transactions With Affiliated Companies (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Investments in and Advances to Affiliates [Table Text Block]	Three months ended March 31, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized March 31, Interest Company 2022 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Cadrenal Therapeutics, Inc. $ — $ — $ — $ — $ — $ 846 $ — $ 846 $ — Total non-controlled affiliates $ — $ — $ — $ — $ — $ 846 $ — $ 846 $ — Three months ended March 31, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized March 31, Dividend Company 2021 Purchases Sales fair value declared gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (50 ) — — 50 — — — Total controlled affiliates $ — $ — $ (50 ) $ — $ — $ 50 $ — $ — $ —

Note 6 - Fair Value (Tables)

Note 6 - Fair Value (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	March 31, 2023 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 684,554 $ 684,554 Warrant investments — 1,020 24,638 25,658 Other investments — — 1,300 1,300 Equity investments 885 — 2,915 3,800 Total investments $ 885 $ 1,020 $ 713,407 $ 715,312 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	March 31, 2023 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 644,854 Discounted Expected Future Cash Flows Hypothetical Market Yield 11% – 20% 14 % 39,700 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 100% 43 % Warrant investments 24,638 Black-Scholes Valuation Model Price Per Share 0.100 –1,89999 $ 62.82 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,915 Last Equity Financing Price Per Share $1.00– $215.03 $ 40.27 Total Level 3 investments $ 713,407 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1.89999 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three months ended March 31, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Purchase of investments 46,998 — 10 — 47,008 Warrants received and classified as Level 3 — 141 — — 141 Principal payments received on investments (39,756 ) — — — (39,756 ) Payment-in-kind interest on investments 1,204 — — — 1,204 Proceeds from sale of investments (6,508 ) (12 ) — — (6,520 ) Net realized gain (loss) on investments 7 (141 ) — — (134 ) Unrealized (depreciation) appreciation included in earnings (4,566 ) (1,490 ) 189 — (5,867 ) Transfer out of debt investments (295 ) (5 ) 300 — — Other 1,012 — — — 1,012 Level 3 assets, end of period $ 684,554 $ 24,638 $ 2,915 $ 1,300 $ 713,407 Three months ended March 31, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 94,485 — — — 94,485 Warrants received and classified as Level 3 — 808 — — 808 Principal payments received on investments (14,095 ) — — (50 ) (14,145 ) Proceeds from sale of investments (21,250 ) (30 ) — — (21,280 ) Net realized gain on investments — 30 — — 30 Unrealized (depreciation) appreciation included in earnings (3,170 ) 1,000 — 50 (2,120 ) Other (1,093 ) — — — (1,093 ) Level 3 assets, end of period $ 492,194 $ 21,645 $ 203 $ 200 $ 514,242

Note 7 - Borrowings (Tables)

Note 7 - Borrowings (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Debt [Table Text Block]	March 31, 2023 December 31, 2022 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 125,000 $ 15,000 $ 110,000 $ 125,000 $ 5,000 $ 120,000 NYL Facility 200,000 176,750 23,250 200,000 176,750 23,250 2019 Asset-Backed Notes 37,791 37,791 — 42,573 42,573 — 2022 Asset-Backed Notes 100,000 100,000 — 100,000 100,000 — 2027 Notes 57,500 57,500 — 57,500 57,500 — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 577,791 444,541 133,250 582,573 439,323 143,250 Unamortized debt issuance costs attributable to term borrowings — (4,896 ) — — (5,245 ) — Total borrowings outstanding, net $ 577,791 $ 439,645 $ 133,250 $ 582,573 $ 434,078 $ 143,250

Note 8 - Financial Instrument_2

Note 8 - Financial Instruments With Off-balance-sheet Risk (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]	March 31, 2023 December 31, 2022 Fair Value of Fair Value of Unfunded Unfunded Principal Commitment Principal Commitment Balance Liability Balance Liability (In thousands) (In thousands) BrightInsight, Inc. $ 18,250 $ 241 $ 21,000 $ 278 Britecore Holdings, Inc. — — 5,000 66 Castle Creek Biosciences 4,000 72 4,000 72 Corinth Medtech, Inc. 200 — — — Divergent Technologies, Inc. 18,750 197 22,500 236 Engage3, LLC 8,000 40 8,000 40 Groundspeed Analytics, Inc. 15,500 150 15,000 150 Hound Labs, Inc. 7,500 88 7,500 88 KSQ Therapeutics, Inc. 10,000 100 10,000 100 Lytics, Inc. 4,000 52 5,000 65 Native Microbials, Inc. — — 7,500 72 Noodle Partners, Inc. 10,000 123 — — Optoro, Inc. 15,000 38 15,000 38 PDS Biotechnology Corporation 10,000 158 10,000 158 Robin Healthcare, Inc. 5,000 50 10,000 100 Scientia Vascular, Inc. 10,000 110 10,000 110 Slingshot Aerospace, Inc. 5,000 63 5,000 64 Swift Health Systems Inc. 18,500 — 25,500 105 Temperpack Technologies, Inc. 6,500 14 9,000 19 Total $ 166,200 $ 1,496 $ 190,000 $ 1,761

Note 10 - Distributions (Tables

Note 10 - Distributions (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Dividends Declared [Table Text Block]	DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Three Months Ended March 31, 2023 2/23/2023 5/18/23 6/14/23 $ 0.11 $ — — $ — 2/23/2023 4/18/23 5/16/23 0.11 — — — 2/23/2023 3/17/23 4/14/23 0.11 3,035 6,894 81 $ 0.33 $ 3,035 6,894 $ 81 Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ 3,040 6,764 $ 75 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 32,659 61,859 $ 754 Ex-Dividend Date Record Date Payment Date Distributions Declared June 15, 2023 June 16, 2023 July 14, 2023 $ 0.11 July 17, 2023 July 18, 2023 August 15, 2023 $ 0.11 August 16, 2023 August 17, 2023 September 15, 2023 $ 0.11

Note 11 - Financial Highlights

Note 11 - Financial Highlights (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Investment Company, Financial Highlights [Table Text Block]	Three months ended March 31, 2023 2022 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.47 $ 11.56 Net investment income 0.46 0.26 Realized loss (0.01 ) — Unrealized depreciation on investments (0.26 ) (0.10 ) Net increase in net assets resulting from operations 0.19 0.16 Distributions declared (1) (0.33 ) (0.30 ) From net investment income (0.33 ) (0.30 ) From net realized gain on investments — — Return of capital — — Other (2) 0.01 0.26 Net asset value at end of period $ 11.34 $ 11.68 Per share market value, beginning of period $ 11.60 $ 15.92 Per share market value, end of period $ 11.28 $ 13.90 Total return based on a market value (3) 0.1 % (10.8 )% Shares outstanding at end of period 28,377,357 23,977,137 Ratios to average net assets: Expenses without incentive value (4) 14.8 % 10.6 % Incentive fees (4) 3.7 % 2.2 % Net expenses (4) 18.5 % 12.8 % Net investment income with incentive fees (4) 16.3 % 8.7 % Net assets at the end of the period $ 321,683 $ 279,989 Average net asset value $ 320,066 $ 262,662 Average debt per share $ 15.61 $ 12.21 Portfolio turnover ratio 4.2 % (5) 2.6 % (5)

Consolidated Schedule of Inve_3

Consolidated Schedule of Investments (Unaudited) (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Nov. 09, 2022	Aug. 13, 2019
Debt Instrument, Face Amount	$ 577,791	$ 582,573
Percentage of Nonqualifying Assets on a Cost Basis	6.30%	6.50%
Percentage of Nonqualifying Assets on a Fair Value Basis	6.20%	6.60%
Asset-backed Notes 2019 [Member]
Debt Instrument, Face Amount	$ 37,791	$ 42,573		$ 160,000
Asset-backed Notes 2019 [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount				$ 100,000
Asset-backed Notes 2022 [Member]
Debt Instrument, Face Amount	$ 100,000	$ 100,000	$ 157,800
Asset-backed Notes 2022 [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount			$ 100,000

Consolidated Schedule of Inve_4

Consolidated Schedule of Investments (Unaudited) - Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments at cost	$ 724,162	$ 721,248
Investments at fair value	715,312	720,026
Investment, Unaffiliated Issuer [Member]
Investments at cost	724,162	721,248
Investments at fair value	714,466	720,026
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Principal Amount
Investments at cost	703,781	701,074
Investments at fair value	684,554	686,458
Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	14,735	14,790
Investments at fair value	25,658	29,712
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member]
Investments at cost	1,200	1,200
Investments at fair value	1,300	1,300
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]
Investments at cost	4,446	4,184
Investments at fair value	2,954	2,556
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at cost	0	0
Investments at fair value	846	0
Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member]
Investments at cost	0
Investments at fair value	846
Biotechnology Sector [Member]
Investments at cost	187,970	193,372
Investments at fair value	186,981	195,006
Medical Device Sector [Member]
Investments at cost	129,102	132,803
Investments at fair value	131,823	135,960
Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	4,158
Investments at fair value	6,603
Software Sector [Member]
Investments at cost	145,706	120,157
Investments at fair value	143,680	118,716
Diagnostics Sector [Member]
Investments at cost	9,862	9,851
Investments at fair value	9,868	9,858
Communications Sector [Member]
Investments at cost	22,913	22,892
Investments at fair value	26,168	26,176
Other Healthcare Sector [Member]
Investments at cost	6,990	7,559
Investments at fair value	1,414	3,870
Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost	309,108	318,172
Investments at fair value	307,749	317,568
Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost		4,197
Investments at fair value		$ 9,792
Number of shares (in shares)
Other Sustainability Sector [Member]
Investments at cost	84,753	$ 84,633
Investments at fair value	83,734	85,524
Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	922
Investments at fair value	739
Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost	32,926	30,729
Investments at fair value	26,137	25,819
Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	424	416
Investments at fair value	1,945	1,953
Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost	277,916	268,468
Investments at fair value	267,673	259,366
Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	9,231	9,249
Investments at fair value	$ 16,371	16,148
Number of shares (in shares)
Data Storage Sector [Member]
Investments at cost	$ 476	476
Investments at fair value	1,302	1,316
Internet and Media Sector [Member]
Investments at cost	329	329
Investments at fair value	1,583	1,159
Sustainability Segment [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost	83,831	83,705
Investments at fair value	82,995	83,705
Sustainability Segment [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost		928
Investments at fair value		$ 1,819
Number of shares (in shares)
Networking Sector [Member]
Investments at cost	10,111	$ 11,831
Investments at fair value	9,984	11,710
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,808	2,610
Semiconductor Sector [Member]
Investments at cost	57	56
Investments at fair value	0	0
Software, Healthcare Information and Service [Member]
Investments at cost	16,498	13,735
Investments at fair value	$ 16,800	$ 14,044
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 2,913	$ 2,885
Investments at cost	2,860	2,853
Investments at fair value	$ 2,779	$ 2,777
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 2,885	$ 2,885
Investments at cost	2,832	2,823
Investments at fair value	2,752	2,750
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	311	311
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	26,444	26,442
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 1,442	$ 1,442
Investments at cost	1,416	1,411
Investments at fair value	$ 1,375	$ 1,374
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 2,885	$ 2,885
Investments at cost	2,829	2,821
Investments at fair value	$ 2,749	$ 2,748
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 2,885	$ 2,885
Investments at cost	2,829	2,821
Investments at fair value	$ 2,749	$ 2,748
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 1,442	$ 1,442
Investments at cost	1,412	1,408
Investments at fair value	$ 1,370	$ 1,371
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 1,442	$ 1,442
Investments at cost	1,412	1,408
Investments at fair value	$ 1,370	$ 1,371
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling	0%	0%
ETP	6%	6%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,922	4,914
Investments at fair value	$ 4,922	$ 4,914
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling	0%	0%
ETP	6%	6%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,461	2,457
Investments at fair value	2,461	2,457
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	264	264
Investments at fair value	$ 28	$ 37
Number of shares (in shares)	318,181	318,181
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%	12.25%
Margin	5.25%	5.25%
Floor	9%	9%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,457	3,349
Investments at fair value	$ 3,457	$ 3,349
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%	12.25%
Margin	5.25%	5.25%
Floor	9%	9%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,457	3,454
Investments at fair value	3,457	3,454
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	71	71
Investments at fair value	$ 81	$ 83
Number of shares (in shares)	135,484	135,484
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.25%
Margin	5.25%
Floor	9%
Ceiling	0%
ETP	5%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,447
Investments at fair value	$ 3,447
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.25%
Margin	5.25%
Floor	9%
Ceiling	0%
ETP	5%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,447
Investments at fair value	$ 3,447
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	11.25%	11.25%
Margin	6%	6%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3%	3%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,520	3,478
Investments at fair value	$ 3,520	$ 3,478
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	11.25%	11.25%
Margin	6%	6%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3%	3%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,239	1,238
Investments at fair value	1,239	1,238
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	70	56
Investments at fair value	$ 237	$ 233
Number of shares (in shares)	33,742	31,966
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11.25%	11.25%
Margin	6%	6%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3%	3%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,717	3,715
Investments at fair value	$ 3,717	$ 3,715
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11.25%	11.25%
Margin	6%	6%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3%	3%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,239	1,238
Investments at fair value	$ 1,239	$ 1,238
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	11.25%	11.25%
Margin	6%	6%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3%	3%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,717	3,715
Investments at fair value	$ 3,717	$ 3,715
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	11.25%	11.25%
Margin	6%	6%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3%	3%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,239	1,238
Investments at fair value	$ 1,239	$ 1,238
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate	11.25%	11.25%
Margin	6%	6%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3%	3%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,701	3,698
Investments at fair value	$ 3,701	$ 3,698
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate	11.25%	11.25%
Margin	6%	6%
Floor	9.50%	9.50%
Ceiling	11.25%	11.25%
ETP	3%	3%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,701	3,698
Investments at fair value	$ 3,701	$ 3,698
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Nine [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling	11.25%
ETP	3%
Maturity Date	Apr. 01, 2028
Principal Amount	$ 3,750
Investments at cost	3,698
Investments at fair value	$ 3,698
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	14%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	3.50%	3.50%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 6,500	$ 6,500
Investments at cost	6,359	6,347
Investments at fair value	$ 6,359	$ 6,347
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	14%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	3.50%	3.50%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 6,000	$ 6,000
Investments at cost	5,869	5,859
Investments at fair value	5,869	5,859
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	455	455
Investments at fair value	$ 196	$ 197
Number of shares (in shares)	516,732	516,732
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.50%	14%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	3.50%	3.50%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,442	2,436
Investments at fair value	$ 2,442	$ 2,436
Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%	12.25%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling	0%	0%
ETP	20%	20%
Maturity Date	Jun. 30, 2023	Sep. 15, 2022
Principal Amount	$ 2,528	$ 2,500
Investments at cost	2,528	2,500
Investments at fair value	$ 2,528	$ 2,500
Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%	12.25%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling	0%	0%
ETP	20%	20%
Maturity Date	Jun. 30, 2023	Sep. 15, 2022
Principal Amount	$ 2,528	$ 2,500
Investments at cost	2,528	2,500
Investments at fair value	$ 2,528	$ 2,500
Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13%
Margin	5.25%
Floor	8.50%
Ceiling	0%
ETP	50%
Maturity Date	Jun. 30, 2023
Principal Amount	$ 200
Investments at cost	200
Investments at fair value	$ 200
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	12%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,946	4,939
Investments at fair value	$ 4,946	$ 4,939
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.75%	12%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,946	4,939
Investments at fair value	4,946	4,939
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	194	194
Investments at fair value	$ 379	$ 385
Number of shares (in shares)	809,931	809,931
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.75%	12%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,940	4,933
Investments at fair value	$ 4,940	$ 4,933
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12.75%	12%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,941	4,933
Investments at fair value	$ 4,941	$ 4,933
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.75%	12.50%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Jan. 01, 2027	Jan. 01, 2027
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,920	4,913
Investments at fair value	$ 4,920	$ 4,913
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	12.75%	12.50%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Jan. 01, 2027	Jan. 01, 2027
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,920	4,913
Investments at fair value	$ 4,920	$ 4,913
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14%	13.50%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	3.50%	3.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,388	2,385
Investments at fair value	$ 2,388	$ 2,385
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14%	13.50%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	3.50%	3.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,473
Investments at fair value	2,476	2,473
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	47	47
Investments at fair value	$ 53	$ 54
Number of shares (in shares)	159,893	159,893
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14%	13.50%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	3.50%	3.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,951	4,946
Investments at fair value	$ 4,951	$ 4,946
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,459	7,455
Investments at fair value	$ 7,459	$ 7,455
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,459	7,455
Investments at fair value	7,459	7,455
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	46	46
Investments at fair value	$ 64	$ 67
Number of shares (in shares)	1,991	1,991
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	13%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,459	7,455
Investments at fair value	7,459	$ 7,455
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Convertible Debt Securities [Member]
Cash Rate		3%
Maturity Date		Jul. 01, 2023
Principal Amount		$ 250
Investments at cost		250
Investments at fair value		$ 306
Axiom Space, Inc [Member] | Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member]
Investments at cost	261
Investments at fair value	$ 306
Number of shares (in shares)	1,810
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	6%	6%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,467	2,463
Investments at fair value	$ 2,361	$ 2,364
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	6%	6%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,467	2,463
Investments at fair value	2,361	2,364
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	48	48
Investments at fair value	$ 31	$ 31
Number of shares (in shares)	27,330	27,330
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,895	4,891
Investments at fair value	$ 4,895	$ 4,891
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,967	4,963
Investments at fair value	4,967	4,963
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	214	214
Investments at fair value	$ 329	$ 335
Number of shares (in shares)	7,404	7,404
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 3,000	$ 3,000
Investments at cost	2,977	2,978
Investments at fair value	$ 2,977	$ 2,978
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,967	4,963
Investments at fair value	$ 4,967	$ 4,963
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,970	4,963
Investments at fair value	$ 4,970	$ 4,963
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	12.88%	12.50%
Margin	6.05%	6.05%
Floor	9.55%	9.55%
Ceiling	13.50%	13.50%
ETP	5.50%	5.50%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 3,000	$ 3,000
Investments at cost	2,980	2,978
Investments at fair value	2,980	2,978
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	250	250
Investments at fair value	$ 250	$ 250
Number of shares (in shares)	1,162	1,162
Meditrina, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 83	$ 83
Investments at fair value	$ 98	$ 101
Number of shares (in shares)	233,993	233,993
Kate Farms, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 102	$ 102
Investments at fair value	$ 1,363	$ 1,370
Number of shares (in shares)	82,965	82,965
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 153	$ 153
Investments at fair value	$ 148	$ 150
Number of shares (in shares)	1,375,727	1,375,727
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.87%	12.37%
Margin	8.20%	8.20%
Floor	10%	10%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jan. 01, 2024	Jan. 01, 2024
Principal Amount	$ 1,250	$ 1,625
Investments at cost	1,239	1,610
Investments at fair value	$ 1,239	$ 1,610
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.87%	12.37%
Margin	8.20%	8.20%
Floor	10%	10%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jan. 01, 2024	Jan. 01, 2024
Principal Amount	$ 83	$ 108
Investments at cost	83	107
Investments at fair value	$ 83	$ 107
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.87%	12.37%
Margin	8.20%	8.20%
Floor	10%	10%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Mar. 01, 2024	Mar. 01, 2024
Principal Amount	$ 1,600	$ 2,000
Investments at cost	1,587	1,983
Investments at fair value	1,587	1,983
Intelepeer Holdings, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	138	139
Investments at fair value	$ 3,251	$ 3,265
Number of shares (in shares)	2,936,535	2,936,535
Engage3, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4.50%	4.50%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,680	3,678
Investments at fair value	$ 3,680	$ 3,678
Engage3, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4.50%	4.50%
Maturity Date	Jul. 01, 2027	Jul. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,720	3,718
Investments at fair value	3,720	3,718
Corvium, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	53	53
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	661,956	661,956
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Nov. 01, 2026	Nov. 01, 2026
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,413	3,360
Investments at fair value	$ 3,413	$ 3,360
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Nov. 01, 2026	Nov. 01, 2026
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,463	3,460
Investments at fair value	3,463	3,460
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	16	16
Investments at fair value	$ 15	$ 16
Number of shares (in shares)	86,066	86,066
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 4,719	$ 4,943
Investments at cost	4,658	4,943
Investments at fair value	$ 46	$ 1,668
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Dec. 31, 2025	Dec. 31, 2025
Principal Amount	$ 2,217	$ 2,500
Investments at cost	2,182	2,467
Investments at fair value	5	832
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	48	47
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	77,690	77,690
PebblePost, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 91	$ 92
Investments at fair value	$ 170	$ 173
Number of shares (in shares)	598,850	598,850
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	11.25%	10.50%
Margin	3.50%	3.50%
Floor	8.25%	8.25%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,977	4,973
Investments at fair value	$ 4,977	$ 4,973
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	11.25%	10.50%
Margin	3.50%	3.50%
Floor	8.25%	8.25%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,977	4,973
Investments at fair value	4,977	4,973
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	69	69
Investments at fair value	$ 206	$ 209
Number of shares (in shares)	145,483	145,483
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11.25%	10.50%
Margin	3.50%	3.50%
Floor	8.25%	8.25%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,481	2,478
Investments at fair value	$ 2,481	$ 2,478
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11.25%	10.50%
Margin	3.50%	3.50%
Floor	8.25%	8.25%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,481	2,478
Investments at fair value	2,481	2,478
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	176	176
Investments at fair value	$ 256	$ 263
Number of shares (in shares)	110,402	110,402
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.57%	12.07%
Margin	4.72%	7.90%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jun. 01, 2024	Jun. 01, 2024
Principal Amount	$ 1,979	$ 1,979
Investments at cost	1,965	1,962
Investments at fair value	$ 1,965	$ 1,962
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.57%	12.07%
Margin	4.72%	7.90%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jun. 01, 2024	Jun. 01, 2024
Principal Amount	$ 1,979	$ 1,979
Investments at cost	1,966	1,963
Investments at fair value	$ 1,966	$ 1,963
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.57%	12.07%
Margin	4.72%	7.90%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Nov. 01, 2025	Nov. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,930	4,923
Investments at fair value	4,930	4,923
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	356	356
Investments at fair value	$ 356	$ 356
Number of shares (in shares)	32,831	32,831
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate	12.57%	12.07%
Margin	4.72%	7.90%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,921	4,912
Investments at fair value	$ 4,921	$ 4,912
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.50%	11.75%
Margin	4.75%	4.75%
Floor	8.50%	8.50%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jan. 01, 2027	Jan. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,601	3,597
Investments at fair value	$ 3,601	$ 3,597
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.50%	11.75%
Margin	4.75%	4.75%
Floor	8.50%	8.50%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jan. 01, 2027	Jan. 01, 2027
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,710	3,706
Investments at fair value	3,710	3,706
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	40	40
Investments at fair value	$ 45	$ 46
Number of shares (in shares)	19,662	19,662
BrightInsight, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 167
Investments at fair value	$ 175
Number of shares (in shares)	85,066
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	12.50%
Margin	5.50%	5.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Aug. 01, 2027	Aug. 01, 2027
Principal Amount	$ 7,000	$ 7,000
Investments at cost	6,663	6,619
Investments at fair value	$ 6,663	$ 6,619
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	12.50%
Margin	5.50%	5.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Aug. 01, 2027	Aug. 01, 2027
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,452	3,448
Investments at fair value	$ 3,452	3,448
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost		160
Investments at fair value		$ 170
Number of shares (in shares)		80,544
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.25%	12.50%
Margin	5.50%	5.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Aug. 01, 2027	Aug. 01, 2027
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,452	3,448
Investments at fair value	$ 3,452	$ 3,448
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%
Margin	5.50%
Floor	9.50%
Ceiling	0%
ETP	3%
Maturity Date	Apr. 01, 2028
Principal Amount	$ 2,750
Investments at cost	2,704
Investments at fair value	2,704
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10%
Ceiling		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,966
Investments at fair value		$ 4,966
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10%
Ceiling		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,966
Investments at fair value		4,966
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	93	93
Investments at fair value	$ 64	$ 64
Number of shares (in shares)	20,000	20,000
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10%
Ceiling		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,979
Investments at fair value		$ 2,979
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10%
Ceiling		0%
ETP		3%
Maturity Date		Dec. 01, 2025
Principal Amount		$ 1,000
Investments at cost		976
Investments at fair value		$ 976
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		13.75%
Margin		6.75%
Floor		10%
Ceiling		0%
ETP		3%
Maturity Date		Feb. 01, 2026
Principal Amount		$ 1,000
Investments at cost		977
Investments at fair value		$ 977
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,704	3,699
Investments at fair value	$ 3,585	$ 3,699
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,704	3,699
Investments at fair value	3,585	3,699
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	61	61
Investments at fair value	$ 72	$ 74
Number of shares (in shares)	201,537	201,537
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	11%	11%
Ceiling	18%	18%
ETP	3%	3%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,802	4,798
Investments at fair value	$ 4,802	$ 4,798
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	11%	11%
Ceiling	18%	18%
ETP	3%	3%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,953	4,948
Investments at fair value	4,953	4,948
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	7	6
Investments at fair value	$ 1	$ 6
Number of shares (in shares)	86,300	86,300
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Convertible Debt Securities [Member]
Cash Rate	15%
Maturity Date	Sep. 10, 2024
Principal Amount	$ 500
Investments at cost	500
Investments at fair value	$ 500
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 10,000	$ 10,000
Investments at cost	9,880	9,872
Investments at fair value	$ 9,880	$ 9,872
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 15,000	$ 15,000
Investments at cost	14,819	14,808
Investments at fair value	14,819	14,808
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	126	126
Investments at fair value	$ 0	$ 125
Number of shares (in shares)	463,915	463,915
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 6,000	$ 6,000
Investments at cost	5,928	5,923
Investments at fair value	$ 5,928	$ 5,923
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 6,000	$ 6,000
Investments at cost	5,928	5,923
Investments at fair value	$ 5,928	$ 5,923
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 4,000	$ 4,000
Investments at cost	3,952	3,949
Investments at fair value	$ 3,952	$ 3,949
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	12.25%	11.75%
Margin	4.25%	4.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	4.25%	4.25%
Maturity Date	Jan. 01, 2028	Jan. 01, 2028
Principal Amount	$ 4,000	$ 4,000
Investments at cost	3,952	3,949
Investments at fair value	$ 3,952	$ 3,949
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	8%	8%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,478	2,476
Investments at fair value	$ 2,478	$ 2,476
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	8%	8%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,478	2,476
Investments at fair value	2,478	2,476
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	98	98
Investments at fair value	$ 120	$ 123
Number of shares (in shares)	605,313	605,313
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	8%	8%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,478	2,476
Investments at fair value	$ 2,478	$ 2,476
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	8%	8%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,459	2,453
Investments at fair value	$ 2,459	$ 2,453
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	8%	8%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,458	2,455
Investments at fair value	2,458	2,455
Medsphere Systems Corporation [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	60
Investments at fair value	$ 354
Number of shares (in shares)	7,097,792
Medsphere Systems Corporation [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost		60
Investments at fair value		$ 359
Number of shares (in shares)		7,097,792
Embody, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14%
Margin		6.50%
Floor		9.75%
Ceiling		0%
ETP		28%
Maturity Date		Aug. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,482
Investments at fair value		2,482
Aterian, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 195	195
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	76,923	76,923
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 4,500	$ 5,000
Investments at cost	4,371	4,857
Investments at fair value	$ 4,352	$ 4,857
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,250	$ 2,500
Investments at cost	2,187	2,430
Investments at fair value	2,177	2,430
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	366	366
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	47,452	47,452
VERO Biotech LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 53	$ 53
Investments at fair value	$ 1	$ 1
Number of shares (in shares)	408	408
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 2,771	$ 3,208
Investments at cost	2,715	3,143
Investments at fair value	$ 2,715	$ 3,143
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 1,000	$ 1,000
Investments at cost	977	974
Investments at fair value	977	974
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	124	124
Investments at fair value	$ 51	$ 113
Number of shares (in shares)	317,647	317,647
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.25%
Margin		6.25%
Floor		9.50%
Ceiling		0%
ETP		4%
Maturity Date		Apr. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,476
Investments at fair value		$ 2,476
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.25%
Margin		6.25%
Floor		9.50%
Ceiling		0%
ETP		4%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,473
Investments at fair value		2,473
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost		35
Investments at fair value		$ 0
Number of shares (in shares)		21,120
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	1.85%	1.85%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,951	4,951
Investments at fair value	$ 3,467	$ 3,834
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.75%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	1.85%	1.85%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,474	2,474
Investments at fair value	1,733	1,916
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	26	26
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	2,672	10,690
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15%	14.50%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,383	7,371
Investments at fair value	$ 7,245	$ 7,371
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15%	14.50%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,383	7,371
Investments at fair value	7,245	7,371
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	490	488
Investments at fair value	$ 1	$ 1,061
Number of shares (in shares)	204,195	204,832
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	15%	14.50%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,383	7,371
Investments at fair value	$ 7,245	$ 7,371
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	15%	14.50%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jul. 01, 2026	Jul. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,912	4,903
Investments at fair value	$ 4,820	$ 4,903
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	15%	14.50%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jul. 01, 2026	Jul. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,912	4,903
Investments at fair value	4,820	4,903
Imunon, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	66	66
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	19,671	16,502
Caastle, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 68	$ 68
Investments at fair value	$ 1,057	$ 1,069
Number of shares (in shares)	268,591	268,591
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling	0%	0%
ETP	6%	6%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 2,500
Investments at cost	4,940	2,466
Investments at fair value	$ 4,940	$ 2,466
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling	0%	0%
ETP	6%	6%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 2,500	$ 5,000
Investments at cost	2,470	4,932
Investments at fair value	2,470	4,932
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	144	148
Investments at fair value	$ 173	$ 179
Number of shares (in shares)	775,000	775,000
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 10,000	$ 10,000
Investments at cost	9,843	9,826
Investments at fair value	$ 9,843	$ 9,826
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 10,000	$ 10,000
Investments at cost	9,843	9,826
Investments at fair value	9,843	9,826
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	275	273
Investments at fair value	$ 287	$ 296
Number of shares (in shares)	639,918	639,918
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,921	4,913
Investments at fair value	$ 4,921	$ 4,913
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,921	4,913
Investments at fair value	$ 4,921	$ 4,913
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,951	4,946
Investments at fair value	$ 4,759	$ 4,946
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,473
Investments at fair value	2,380	2,473
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	67	67
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	39,774	39,774
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,953	4,947
Investments at fair value	$ 4,761	$ 4,947
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,953	4,947
Investments at fair value	4,761	4,947
Lumithera, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Royalty Agreement [Member]
Investments at cost	1,200	1,200
Investments at fair value	1,100	1,100
Lumithera, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	2,000	2,000
Investments at fair value	$ 1,700	$ 1,700
Number of shares (in shares)	392,651	392,651
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%	12.50%
Margin	5%	5%
Floor	5%	5%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2027	Mar. 01, 2027
Principal Amount	$ 2,000	$ 2,000
Investments at cost	1,165	1,082
Investments at fair value	$ 1,165	$ 1,082
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%	12.50%
Margin	5%	5%
Floor	5%	5%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2027	Mar. 01, 2027
Principal Amount	$ 3,000	$ 3,000
Investments at cost	1,748	1,623
Investments at fair value	1,748	1,623
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	2,942	2,947
Investments at fair value	$ 2,674	$ 2,947
Number of shares (in shares)	1,312,500	1,312,500
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11.50%	11%
Margin	3.50%	3.50%
Floor	10.50%	10.50%
Ceiling	0%	0%
ETP	7.78%	7.78%
Maturity Date	Feb. 01, 2028	Feb. 01, 2028
Principal Amount	$ 2,813	$ 2,813
Investments at cost	2,813	2,813
Investments at fair value	$ 2,813	$ 2,813
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11.50%	11%
Margin	3.50%	3.50%
Floor	10.50%	10.50%
Ceiling	0%	0%
ETP	7.78%	7.78%
Maturity Date	Feb. 01, 2028	Feb. 01, 2028
Principal Amount	$ 2,813	$ 2,813
Investments at cost	2,813	2,813
Investments at fair value	$ 2,813	$ 2,813
CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.25%	14.75%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,464	3,461
Investments at fair value	3,464	3,461
CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	22	20
Investments at fair value	$ 0	$ 61
Number of shares (in shares)	17,605	17,605
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	12.25%
Margin	4.75%	4.75%
Floor	8.50%	8.50%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	May 01, 2027	May 01, 2027
Principal Amount	$ 6,250	$ 6,250
Investments at cost	6,082	6,077
Investments at fair value	$ 6,082	$ 6,077
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.75%	12.25%
Margin	4.75%	4.75%
Floor	8.50%	8.50%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	May 01, 2027	May 01, 2027
Principal Amount	$ 6,250	$ 6,250
Investments at cost	6,182	6,177
Investments at fair value	6,182	6,177
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	50	51
Investments at fair value	$ 56	$ 60
Number of shares (in shares)	48,076	48,077
ZetrOZ, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Royalty Agreement [Member]
Investments at cost	$ 0	$ 0
Investments at fair value	$ 200	$ 200
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,318	2,482
Investments at fair value	$ 2,318	$ 2,482
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,318	2,482
Investments at fair value	2,318	2,482
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	30	30
Investments at fair value	$ 124	$ 125
Number of shares (in shares)	46,745	46,745
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 221	$ 221
Investments at fair value	$ 221	$ 226
Number of shares (in shares)	7,972,222	7,972,222
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.67%	12.17%
Margin	8%	8%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	10.36%	10.36%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 3,960	$ 3,960
Investments at cost	3,904	3,898
Investments at fair value	$ 3,904	$ 3,898
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.67%	12.17%
Margin	8%	8%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	10.36%	10.36%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 3,960	$ 3,960
Investments at cost	3,904	3,898
Investments at fair value	3,904	3,898
Mustang Bio, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	141	146
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	252,161	252,161
LiquiGlide, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 39	$ 39
Investments at fair value	$ 53	$ 55
Number of shares (in shares)	61,359	61,539
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	12.75%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Nov. 01, 2026	Nov. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,707	3,630
Investments at fair value	$ 3,707	$ 3,630
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	12.75%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Nov. 01, 2026	Nov. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,472	2,469
Investments at fair value	2,472	2,469
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	64	64
Investments at fair value	$ 159	$ 162
Number of shares (in shares)	103,679	103,679
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.75%	2.75%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 5,000	$ 2,500
Investments at cost	4,935	2,463
Investments at fair value	$ 4,935	$ 2,463
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.75%	2.75%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 5,000
Investments at cost	2,467	4,927
Investments at fair value	2,467	4,927
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	214	214
Investments at fair value	$ 354	$ 361
Number of shares (in shares)	681	681
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.75%	2.75%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,932	4,924
Investments at fair value	$ 4,932	$ 4,924
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.75%	2.75%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,466	2,462
Investments at fair value	$ 2,466	$ 2,462
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	11.75%	10%
Ceiling	0%	0%
ETP	2.75%	2.75%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,909	4,900
Investments at fair value	$ 4,909	$ 4,900
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	13.50%	13%
Margin	5.50%	5.50%
Floor	11.75%	10%
Ceiling	0%	0%
ETP	2.75%	2.75%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,454	2,450
Investments at fair value	$ 2,454	$ 2,450
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	14%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Mar. 01, 2026	Mar. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,953	4,947
Investments at fair value	$ 4,953	$ 4,947
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	14%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Mar. 01, 2026	Mar. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,477	2,474
Investments at fair value	2,477	2,474
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	35	34
Investments at fair value	$ 40	$ 41
Number of shares (in shares)	101,308	101,308
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	3.75%	3.75%
Maturity Date	Sep. 01, 2026	Sep. 01, 2026
Principal Amount	$ 10,000	$ 10,000
Investments at cost	9,714	9,701
Investments at fair value	$ 9,714	$ 9,701
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	3.75%	3.75%
Maturity Date	Sep. 01, 2026	Sep. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,702	3,697
Investments at fair value	3,702	3,697
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	160	160
Investments at fair value	$ 937	$ 3,024
Number of shares (in shares)	299,848	299,848
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	3.75%	3.75%
Maturity Date	Sep. 01, 2026	Sep. 01, 2026
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,702	3,697
Investments at fair value	$ 3,702	$ 3,697
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 3,246	$ 3,210
Investments at cost	3,162	3,151
Investments at fair value	$ 0	$ 0
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 2,963	$ 2,963
Investments at cost	2,886	2,886
Investments at fair value	0	0
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost		103
Investments at fair value		$ 0
Number of shares (in shares)		553,710
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	401	$ 399
Investments at fair value	$ 128	$ 648
Number of shares (in shares)	254,609	203,017
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 4,667	$ 4,667
Investments at cost	4,606	4,597
Investments at fair value	$ 4,606	$ 4,597
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 4,667	$ 4,667
Investments at cost	4,606	4,597
Investments at fair value	$ 4,606	$ 4,597
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,333
Investments at cost	2,287	2,280
Investments at fair value	$ 2,287	$ 2,280
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,333
Investments at cost	2,287	2,280
Investments at fair value	$ 2,287	$ 2,280
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Five [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,333
Investments at cost	2,282	2,274
Investments at fair value	$ 2,282	$ 2,274
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Six [Member]
Cash Rate	13.17%	12.67%
Margin	8.50%	8.50%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,333
Investments at cost	2,282	2,274
Investments at fair value	$ 2,282	$ 2,274
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,706	3,697
Investments at fair value	$ 3,706	$ 3,697
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,720	3,717
Investments at fair value	3,720	3,717
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	118	126
Investments at fair value	$ 259	$ 268
Number of shares (in shares)	34,604	35,906
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,431	7,424
Investments at fair value	$ 7,431	$ 7,424
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,715	3,712
Investments at fair value	$ 3,715	$ 3,712
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,715	3,712
Investments at fair value	3,715	3,712
Getaround, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	253	253
Investments at fair value	$ 25	$ 57
Number of shares (in shares)	87,082	87,082
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,961	4,954
Investments at fair value	$ 4,961	$ 4,954
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.75%	14.25%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,480	2,477
Investments at fair value	2,480	2,477
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	29	29
Investments at fair value	$ 36	$ 37
Number of shares (in shares)	143	143
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Nov. 01, 2026	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,411	2,396
Investments at fair value	$ 2,411	$ 2,396
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13%
Margin	6%	6%
Floor	12.25%	12.25%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Dec. 01, 2026	Dec. 01, 2026
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,232	1,231
Investments at fair value	1,232	1,231
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	43	40
Investments at fair value	$ 46	$ 44
Number of shares (in shares)	85,543	80,197
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%
Margin	6%
Floor	12.25%
Ceiling	0%
ETP	3%
Maturity Date	Apr. 01, 2027
Principal Amount	$ 1,000
Investments at cost	984
Investments at fair value	984
Rocket Pharmaceuticals Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	17	$ 17
Investments at fair value	$ 2	$ 14
Number of shares (in shares)	7,051	7,051
SnagAJob.com, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	$ 9	$ 8
Investments at fair value	$ 83	$ 83
Number of shares (in shares)	82,974	82,974
Lyrical Foods, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	10.50%	10%
Margin	2.50%	6.75%
Floor	8%	10%
Ceiling	0%	0%
ETP	0%	0%
Maturity Date	Sep. 01, 2027	Sep. 01, 2027
Principal Amount	$ 2,598	$ 2,500
Investments at cost	2,586	2,588
Investments at fair value	$ 2,330	$ 2,279
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.25%	2%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 5,169	$ 5,000
Investments at cost	5,121	4,943
Investments at fair value	$ 4,883	$ 4,715
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.25%	2%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,067	$ 2,000
Investments at cost	2,050	1,981
Investments at fair value	1,955	1,890
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	197	197
Investments at fair value	$ 17	$ 17
Number of shares (in shares)	1,261,253	1,261,253
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.25%	2%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,584	$ 2,500
Investments at cost	2,564	2,477
Investments at fair value	$ 2,446	$ 2,363
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.25%	2%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 3,101	$ 3,000
Investments at cost	3,076	2,971
Investments at fair value	$ 2,934	$ 2,835
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.25%	2%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,584	$ 2,500
Investments at cost	2,548	2,459
Investments at fair value	$ 2,430	$ 2,345
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.25%	2%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,584	$ 2,500
Investments at cost	2,548	2,459
Investments at fair value	$ 2,430	$ 2,345
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.25%	2%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 5,169	$ 5,000
Investments at cost	5,093	4,914
Investments at fair value	$ 4,859	$ 4,688
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate	13.50%	12.75%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling	0%	0%
ETP	5.25%	2%
Maturity Date	Oct. 31, 2023	Dec. 30, 2022
Principal Amount	$ 2,584	$ 2,500
Investments at cost	2,545	2,456
Investments at fair value	$ 2,428	$ 2,342
Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Aug. 01, 2027	Aug. 01, 2027
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,355	2,347
Investments at fair value	2,355	2,347
Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	104	104
Investments at fair value	$ 104	$ 104
Number of shares (in shares)	6,600	6,600
vTv Therapeutics Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 44	$ 44
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	95,293	95,293
Tigo Energy, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member]
Investments at cost	$ 8	$ 8
Investments at fair value	$ 27	$ 27
Number of shares (in shares)	22,313	22,313
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15%	14.25%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 2,300	$ 2,700
Investments at cost	2,277	2,673
Investments at fair value	$ 2,277	$ 2,673
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15%	14.25%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 2,300	$ 2,700
Investments at cost	2,277	2,673
Investments at fair value	2,277	2,673
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	57	57
Investments at fair value	$ 427	$ 429
Number of shares (in shares)	553,778	553,778
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	15%	14.25%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 2,900	$ 3,000
Investments at cost	2,870	2,967
Investments at fair value	$ 2,870	2,967
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%
Margin	5%
Floor	12%
Ceiling	0%
ETP	3%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 10,000
Investments at cost	9,733
Investments at fair value	$ 9,733
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%
Margin	5%
Floor	12%
Ceiling	0%
ETP	3%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 5,000
Investments at cost	4,928
Investments at fair value	4,928
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	116
Investments at fair value	$ 116
Number of shares (in shares)	84,037
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13%
Margin	5%
Floor	12%
Ceiling	0%
ETP	3%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 5,000
Investments at cost	4,928
Investments at fair value	4,928
Xeris Pharmaceuticals, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	72	72
Investments at fair value	$ 9	$ 3
Number of shares (in shares)	126,000	126,000
Branded Online, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member]
Investments at cost	$ 1,075	$ 1,079
Investments at fair value	$ 14	$ 83
Number of shares (in shares)	5,398	108,004
Quip NYC Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 325	$ 325
Investments at fair value	$ 532	$ 534
Number of shares (in shares)	6,191	6,191
AccuVein Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 24	$ 24
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	1,175	1,175
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	17.43%	16.93%
Margin	9.43%	9.43%
Floor	12.68%	12.68%
Ceiling	0%	0%
ETP	50.43%	50.43%
Maturity Date	Dec. 31, 2022	Dec. 31, 2022
Principal Amount	$ 3,284	$ 3,295
Investments at cost	3,284	3,295
Investments at fair value	2,750	3,295
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	46	46
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	82,967	82,967
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred and Common Stock [Member]
Investments at cost	$ 229
Investments at fair value	$ 0
Number of shares (in shares)	72,638,663
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]
Investments at cost		$ 230
Investments at fair value		$ 0
Number of shares (in shares)		72,638,663
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.75%	15.25%
Margin	7.75%	7.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	0%	0%
Maturity Date	May 01, 2027	Jul. 01, 2025
Principal Amount	$ 1,065	$ 2,500
Investments at cost	1,041	2,473
Investments at fair value	$ 1,041	$ 2,473
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15.75%	15.25%
Margin	7.75%	7.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	0%	0%
Maturity Date	May 01, 2027	Jul. 01, 2025
Principal Amount	$ 533	$ 1,250
Investments at cost	520	1,236
Investments at fair value	520	1,236
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	32	32
Investments at fair value	$ 111	$ 22
Number of shares (in shares)	171,081	171,081
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	15.75%	15.25%
Margin	7.75%	7.75%
Floor	11%	11%
Ceiling	0%	0%
ETP	0%	0%
Maturity Date	May 01, 2027	Jul. 01, 2025
Principal Amount	$ 533	$ 1,250
Investments at cost	521	1,236
Investments at fair value	521	1,236
Aerin Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	66	64
Investments at fair value	$ 1,196	$ 1,200
Number of shares (in shares)	1,818,183	1,818,183
Lotame Solutions, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 19	$ 22
Investments at fair value	$ 53	$ 312
Number of shares (in shares)	71,305	288,115
Lotame Solutions, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member]
Investments at cost	$ 5
Investments at fair value	$ 193
Number of shares (in shares)	66,127
Updater, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	$ 34	$ 34
Investments at fair value	$ 42	$ 42
Number of shares (in shares)	108,333	108,333
Reputation Institute, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15%	14.25%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling	0%	0%
ETP	3%	3%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 4,833	$ 5,000
Investments at cost	4,772	4,932
Investments at fair value	4,772	4,932
Reputation Institute, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	61	56
Investments at fair value	$ 46	$ 39
Number of shares (in shares)	3,731	3,731
CPG Beyond, Inc [Member] | Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 242	$ 242
Investments at fair value	$ 903	$ 909
Number of shares (in shares)	500,000	500,000
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,940	4,870
Investments at fair value	$ 4,940	$ 4,870
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,940	4,933
Investments at fair value	4,940	4,933
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	123	123
Investments at fair value	$ 135	$ 133
Number of shares (in shares)	309,208	309,208
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,875	4,933
Investments at fair value	$ 4,875	$ 4,933
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.75%	13.25%
Margin	5.75%	5.75%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,940	4,933
Investments at fair value	4,940	$ 4,933
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12.75%
Margin		5.75%
Floor		9%
Ceiling		0%
ETP		7%
Maturity Date		Nov. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,475
Investments at fair value		$ 2,475
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12.75%
Margin		5.75%
Floor		9%
Ceiling		0%
ETP		7%
Maturity Date		Nov. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,489
Investments at fair value		2,489
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	86	84
Investments at fair value	$ 1,862	$ 1,864
Number of shares (in shares)	12,153	12,153
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12.75%
Margin		5.75%
Floor		9%
Ceiling		0%
ETP		7%
Maturity Date		Nov. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,473
Investments at fair value		2,473
Silk, Inc [Member] | Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost		234
Investments at fair value		$ 407
Number of shares (in shares)		442,110
Silk, Inc [Member] | Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	$ 234
Investments at fair value	$ 399
Number of shares (in shares)	442,110
Global Worldwide LLC [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 75	$ 75
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	245,810	245,810
Cadrenal Therapeutics, Inc. [Member] | Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at fair value	$ 846	$ 0
Cadrenal Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Common Stock [Member]
Investments at cost	0
Investments at fair value	$ 846
Number of shares (in shares)	600,000
Spineology, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15%	14.50%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	1%	1%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,969	4,966
Investments at fair value	$ 4,969	$ 4,966
Spineology, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15%	14.50%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling	0%	0%
ETP	1%	1%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,483	2,481
Investments at fair value	2,483	2,481
Rocket Lawyer Incorporated [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	92	92
Investments at fair value	$ 352	$ 357
Number of shares (in shares)	261,721	261,721
Skillshare, Inc [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 162	$ 162
Investments at fair value	$ 1,231	$ 802
Number of shares (in shares)	139,074	139,074
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 3,208	$ 3,500
Investments at cost	3,183	3,472
Investments at fair value	$ 3,183	$ 3,472
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Feb. 01, 2025	Dec. 01, 2025
Principal Amount	$ 3,208	$ 2,500
Investments at cost	3,183	2,472
Investments at fair value	3,183	2,472
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	64	64
Investments at fair value	$ 140	$ 83
Number of shares (in shares)	682	682
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	13.50%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Dec. 01, 2025	Dec. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,475	2,472
Investments at fair value	$ 2,475	$ 2,472
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%
Margin	6.50%
Floor	9.75%
Ceiling	0%
ETP	4%
Maturity Date	Dec. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,475
Investments at fair value	$ 2,475
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 2,833	$ 3,333
Investments at cost	2,793	3,286
Investments at fair value	$ 2,793	$ 3,286
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 2,833	$ 3,333
Investments at cost	2,793	3,286
Investments at fair value	2,793	3,286
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	364	364
Investments at fair value	$ 237	$ 243
Number of shares (in shares)	344,102	344,102
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,417	$ 1,667
Investments at cost	1,395	1,641
Investments at fair value	$ 1,395	$ 1,641
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,417	$ 1,667
Investments at cost	1,395	1,641
Investments at fair value	$ 1,395	$ 1,641
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14%	13.25%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,417	$ 1,667
Investments at cost	1,371	1,613
Investments at fair value	1,371	1,613
CVRx, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	76	76
Investments at fair value	$ 72	$ 394
Number of shares (in shares)	47,410	47,410
Halio, Inc [Member] | Power Management Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 1,585	$ 1,585
Investments at fair value	$ 2,808	$ 2,610
Number of shares (in shares)	5,002,574	5,002,574
Avalanche Technology, Inc [Member] | Semiconductor Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost	$ 57	$ 56
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	6,081	6,081
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	13.75%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Mar. 01, 2026	Mar. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,488	2,421
Investments at fair value	$ 2,488	$ 2,421
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	13.75%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling	0%	0%
ETP	5%	5%
Maturity Date	Mar. 01, 2026	Mar. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,488	2,487
Investments at fair value	2,488	2,487
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	21	21
Investments at fair value	$ 67	$ 69
Number of shares (in shares)	77,828	77,828
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.50%
Margin	6.75%
Floor	10%
Ceiling	0%
ETP	3%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 2,500
Investments at cost	2,467
Investments at fair value	$ 2,467
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.50%
Margin	6.75%
Floor	10%
Ceiling	0%
ETP	3%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 2,500
Investments at cost	2,467
Investments at fair value	2,467
E La Carte, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member]
Investments at cost	60	$ 60
Investments at fair value	$ 0	$ 3
Number of shares (in shares)	147,361	147,361
Revinate Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 44	$ 46
Investments at fair value	$ 97	$ 99
Number of shares (in shares)	682,034	682,034
Riv Data Corp [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 12	$ 12
Investments at fair value	$ 296	$ 296
Number of shares (in shares)	321,428	321,428
SIGNiX, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 225	$ 225
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	186,235	186,235
Skyword, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost		$ 48
Investments at fair value		$ 1
Number of shares (in shares)		301,055
Topia Mobility, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 138	$ 138
Investments at fair value	$ 0	$ 0
Number of shares (in shares)	3,049,607	3,049,607
xAd, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 177	$ 177
Investments at fair value	$ 11	$ 12
Number of shares (in shares)	4,343,348	4,343,348

Consolidated Schedule of Inve_5

Consolidated Schedule of Investments (Unaudited) - Investments (Details) (Parentheticals)	Mar. 31, 2023	Dec. 31, 2022
NAV %	222.40%	226.10%
Investment, Unaffiliated Issuer [Member]
NAV %	221.10%	226.10%
Investment, Unaffiliated Issuer [Member] | Warrant [Member]
NAV %	8%	9.40%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Healthcare Sector [Member]
NAV %	0.60%	0.60%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Life Science [Member]
NAV %	2.10%	3.10%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Sustainability Segment [Member]
NAV %	0.20%	0.60%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Technology Sector [Member]
NAV %	5.10%	5.10%
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member]
NAV %	0.40%	0.40%
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]
NAV %	0.90%	0.80%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
NAV %	212.80%	215.50%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Healthcare Sector [Member]
NAV %	8.10%	8.10%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Life Science [Member]
NAV %	95.70%	99.70%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Sustainability Segment [Member]
NAV %	25.80%	26.30%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Technology Sector [Member]
NAV %	83.20%	81.40%
Investment, Affiliated Issuer, Noncontrolled [Member]
NAV %	0.30%
Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member] | Life Science [Member]
NAV %	0.30%

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		23 Months Ended
	Mar. 14, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Dec. 31, 2022	Apr. 28, 2022	Aug. 02, 2021
Investments, Nonaccrual, Interest Income		$ 0	$ 0
Investment, Nonaccrual, Income Not Received in Cash, Percent		6.30%	9.50%
Debt Issuance Costs, Net		$ 6,600		$ 6,600	$ 7,100
Accumulated Amortization, Debt Issuance Costs		5,300		$ 5,300	4,800
Amortization of Debt Issuance Costs		$ 478	$ 336
Federal Excise Tax, Percent		4%		4%
Investment Income, Operating, Tax Expense (Benefit)		$ 184	100
Unrecognized Tax Benefits, Ending Balance		$ 0		$ 0	0
Open Tax Year		2019 2020 2021
Proceeds from Issuance of Common Stock		$ 7,174	$ 38,187
Stock Repurchase Program, Remaining Authorized Repurchase Amount						$ 5,000
Stock Repurchased During Period, Shares (in shares)		0	0	167,465
Stock Repurchased During Period, Per Share (in dollars per share)				$ 11.22
Stock Repurchased During Period, Value				$ 1,900
The 2021 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value							$ 100,000
Stock Issued During Period, Shares, New Issues (in shares)		605,848	250,171
Proceeds from Issuance of Common Stock		$ 7,200	$ 3,900
Payments of Stock Issuance Costs		200	$ 100
Equity Sales Agreement, Remaining Amount Available for Issuance		24,100		24,100
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,500,000
Proceeds from Issuance of Common Stock	$ 34,300
Shares Issued, Price Per Share (in dollars per share)	$ 14.35
Three Investments [Member]
Investments, Cost, Nonaccrual Status		20,300		20,300	20,900
Investments, Fair Value, Nonaccrual Status		$ 5,300		$ 5,300	$ 8,300

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	May 25, 2023	Dec. 31, 2022
Management Fee Payable	$ 1,059			$ 1,065
Management Fee Expense	3,201	$ 2,244
Incentive Fee Payable	2,978			1,392
Administrative Fees Expense	$ 440	362
Investment Management Agreement [Member]
Base Management Fee, Annual, Percent	2%
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million	1.60%
Management Fee Payable	$ 1,100			1,100
Management Fee Expense	$ 3,200	2,200
Incentive Fee to Pre-incentive Net Investment Income	20%
Pre-Incentive Fee Net Investment Income, Hurdle Rate	1.75%
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized	7%
Pre-Incentive Fee Net Investment Income, Catch-up, Percent	100%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up	2.1875%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized	8.75%
Incentive Fee Expense	$ 3,000	1,400
Incentive Fee Cap and Deferral Mechanism Reduction to Expense	200
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	1,300
Incentive Fee Payable	3,000			$ 1,400
Administration Agreement [Member]
Administrative Fees Expense	$ 400	$ 400
Affiliate of Monroe Capital LLC [Member] | Forecast [Member] | Horizon Technology Finance Management LLC (the Advisor) [Member]
Subsidiary, Ownership Percentage, Parent			100%

Note 4 - Investments - Investme

Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments at cost	$ 724,162	$ 721,248
Investments at fair value	715,312	720,026
Biotechnology Sector [Member]
Investments at cost	187,970	193,372
Investments at fair value	186,981	195,006
Medical Device Sector [Member]
Investments at cost	129,102	132,803
Investments at fair value	131,823	135,960
Communications Sector [Member]
Investments at cost	22,913	22,892
Investments at fair value	26,168	26,176
Consumer-related Sector [Member]
Investments at cost	107,802	121,961
Investments at fair value	99,140	114,050
Data Storage Sector [Member]
Investments at cost	476	476
Investments at fair value	1,302	1,316
Internet and Media Sector [Member]
Investments at cost	329	329
Investments at fair value	1,583	1,159
Networking Sector [Member]
Investments at cost	10,111	11,831
Investments at fair value	9,984	11,710
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,808	2,610
Semiconductor Sector [Member]
Investments at cost	57	56
Investments at fair value	0	0
Software Sector [Member]
Investments at cost	145,706	120,157
Investments at fair value	143,680	118,716
Energy Efficiency [Member]
Investments at cost	8	8
Investments at fair value	27	27
Other Sustainability Sector [Member]
Investments at cost	84,753	84,633
Investments at fair value	83,734	85,524
Diagnostics Sector [Member]
Investments at cost	9,862	9,851
Investments at fair value	9,868	9,858
Other Healthcare Sector [Member]
Investments at cost	6,990	7,559
Investments at fair value	1,414	3,870
Software, Healthcare Information and Service [Member]
Investments at cost	16,498	13,735
Investments at fair value	16,800	14,044
Debt [Member]
Investments at cost	703,781	701,074
Investments at fair value	684,554	686,458
Warrant [Member]
Investments at cost	14,735	14,790
Investments at fair value	25,658	29,712
Other Debt Obligations [Member]
Investments at cost	1,200	1,200
Investments at fair value	1,300	1,300
Equity Securities [Member]
Investments at cost	4,446	4,184
Investments at fair value	$ 3,800	$ 2,556

Note 5 - Transactions With Af_3

Note 5 - Transactions With Affiliated Companies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)		$ 0
Investment, Affiliated Issuer, Controlled [Member]
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)	$ 0

Note 5 - Transactions With Af_4

Note 5 - Transactions With Affiliated Companies - Investments in Affiliated Companies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investments, fair value	$ 720,026
Unrealized Gain (Loss) on Investments	(7,537)	$ (2,237)
Net realized gain (loss) on investments	(168)	30
Investments, fair value	715,312
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments, fair value	0
Purchases	0
Principal payments	0
Transfers in/(out) at fair value	0
Discount accretion	0
Unrealized Gain (Loss) on Investments	846	0
Net realized gain (loss) on investments	0
Investments, fair value	846
Interest income	0
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member]
Investments, fair value	0
Purchases	0
Principal payments	0
Transfers in/(out) at fair value	0
Discount accretion	0
Unrealized Gain (Loss) on Investments	846
Net realized gain (loss) on investments	0
Investments, fair value	846
Interest income	0
Investment, Affiliated Issuer, Controlled [Member]
Investments, fair value		0
Purchases		0
Principal payments		(50)
Transfers in/(out) at fair value		0
Discount accretion		0
Unrealized Gain (Loss) on Investments	$ 0	50
Net realized gain (loss) on investments		0
Investments, fair value		0
Interest income		0
Investment, Affiliated Issuer, Controlled [Member] | HESP LLC [Member]
Investments, fair value		0
Purchases		0
Principal payments		(50)
Transfers in/(out) at fair value		0
Discount accretion		0
Unrealized Gain (Loss) on Investments		50
Net realized gain (loss) on investments		0
Investments, fair value		0
Interest income		$ 0

Note 6 - Fair Value (Details Te

Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net	$ 0	$ 0
Unrealized Gain (Loss) on Investments	(7,537)	(2,237)
Fair Value, Inputs, Level 3 [Member] | Debt [Member]
Unrealized Gain (Loss) on Investments	(4,600)	(3,300)
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Unrealized Gain (Loss) on Investments	(1,400)	$ 1,000
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member]
Unrealized Gain (Loss) on Investments	$ 200
The 2026 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 23.39
The 2026 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure	$ 53,800
The 2027 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 24
The 2027 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure	$ 55,200
Asset-backed Notes 2019 [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure	37,800
Asset-backed Notes 2022 [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure	$ 100,000
Measurement Input, Hypothetical Market Yields [Member]
Debt Instrument, Measurement Input			0.25

Note 6 - Fair Value - Assets at

Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Recurring [Member]
Investments, fair value	$ 715,312	$ 720,026
Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	684,554	686,458
Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	25,658	29,712
Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	1,300	1,300
Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	3,800	2,556
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Investments, fair value	885	140
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	885	140
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Investments, fair value	1,020	3,567
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	1,020	3,567
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Investments, fair value	713,407	716,319
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Investments, fair value	713,407	716,319
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	684,554	686,458
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	24,638	26,145
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	1,300	1,300
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	$ 2,915	$ 2,416

Note 6 - Fair Value - Significa

Note 6 - Fair Value - Significant Level 3 Fair Value Measurement Inputs (Details) - Fair Value, Inputs, Level 3 [Member]		Mar. 31, 2023 USD ($)		Dec. 31, 2022 USD ($)
Investments, fair value		$ 713,407,000		$ 716,319,000
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member]
Investments, fair value		$ 644,854,000		$ 669,617,000
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input		0.11		0.03
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input		0.20	[1]	0.22
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member]
Investments, measurement input		0.14		0.14	[1]
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value		$ 39,700,000		$ 16,545,000
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]
Investments, measurement input		0.10		0.10
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]
Investments, measurement input		1	[1]	0.75
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input		0.43		0.31	[1]
Debt [Member] | Black-scholes Valuation Model [Member]
Investments, fair value				$ 26,145,000
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input				0.28
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input				0.20
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input				0
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]
Investments, measurement input				1
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input				1.899
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]
Investments, measurement input				5
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]			58.52
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input	[1]			0.28
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	[1]			0.20
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]
Investments, measurement input	[1]			3
Debt [Member] | Convertible Note Analysis [Member]
Investments, fair value				$ 296,000
Debt [Member] | Convertible Note Analysis [Member] | Measurement Input, Share Price [Member]
Investments, measurement input				168.93
Debt [Member] | Convertible Note Analysis [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]			168.93
Warrant [Member] | Black-scholes Valuation Model [Member]
Investments, fair value		$ 24,638,000
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input		0.28
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input		0.20
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		0.10
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input		0.20
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]
Investments, measurement input		1
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]	1,899
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]
Investments, measurement input	[1]	5
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		62.82
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input		0.28
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]
Investments, measurement input		3
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value		$ 1,300,000		$ 1,300,000
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member]
Investments, measurement input		1		1
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input		0.25		0.25
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input		1		1	[1]
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input		0.25		0.25	[1]
Equity Securities [Member] | Last Equity Financing [Member]
Investments, fair value		$ 2,915,000		$ 24.16
Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		40.27		26.93	[1]
[1]Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Note 6 - Fair Value - Reconcili

Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Balance	$ 716,319	$ 457,557
Purchase of investments	47,008	94,485
Warrants received and classified as Level 3	141	808
Principal payments received on investments	(39,756)	14,145
Payment-in-kind interest on investments	1,204
Proceeds from sale of investments	(6,520)	21,280
Net realized gain (loss) on investments	(134)	30
Unrealized (depreciation) appreciation included in earnings	(5,867)	(2,120)
Transfer out of debt investments	0
Other	1,012	(1,093)
Balance	713,407	514,242
Principal payments received on investments	39,756	(14,145)
Proceeds from sale of investments	6,520	(21,280)
Debt [Member]
Balance	686,458	437,317
Purchase of investments	46,998	94,485
Warrants received and classified as Level 3	0	0
Principal payments received on investments	(39,756)	14,095
Payment-in-kind interest on investments	1,204
Proceeds from sale of investments	(6,508)	21,250
Net realized gain (loss) on investments	7	0
Unrealized (depreciation) appreciation included in earnings	(4,566)	(3,170)
Transfer out of debt investments	(295)
Other	1,012	(1,093)
Balance	684,554	492,194
Principal payments received on investments	39,756	(14,095)
Proceeds from sale of investments	6,508	(21,250)
Warrant [Member]
Balance	26,145	19,837
Purchase of investments	0	0
Warrants received and classified as Level 3	141	808
Principal payments received on investments	0	0
Payment-in-kind interest on investments	0
Proceeds from sale of investments	(12)	30
Net realized gain (loss) on investments	(141)	30
Unrealized (depreciation) appreciation included in earnings	(1,490)	1,000
Transfer out of debt investments	(5)
Other	0	0
Balance	24,638	21,645
Principal payments received on investments	0	0
Proceeds from sale of investments	12	(30)
Equity Securities [Member]
Balance	2,416	203
Purchase of investments	10	0
Warrants received and classified as Level 3	0	0
Principal payments received on investments	0	0
Payment-in-kind interest on investments	0
Proceeds from sale of investments	0	0
Net realized gain (loss) on investments	0	0
Unrealized (depreciation) appreciation included in earnings	189	0
Transfer out of debt investments	300
Other	0	0
Balance	2,915	203
Principal payments received on investments	0	0
Proceeds from sale of investments	0	0
Other Investments [Member]
Balance	1,300	200
Purchase of investments	0	0
Warrants received and classified as Level 3	0	0
Principal payments received on investments	0	50
Payment-in-kind interest on investments	0
Proceeds from sale of investments	0	0
Net realized gain (loss) on investments	0	0
Unrealized (depreciation) appreciation included in earnings	0	50
Transfer out of debt investments	0
Other	0	0
Balance	1,300	200
Principal payments received on investments	0	(50)
Proceeds from sale of investments	$ 0	$ 0

Note 7 - Borrowings (Details Te

Note 7 - Borrowings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	12 Months Ended	21840 Months Ended
	Feb. 25, 2022	Apr. 21, 2020	Mar. 31, 2023	Dec. 31, 2021	Feb. 25, 2022	Dec. 31, 2022	Nov. 09, 2022	Jun. 15, 2022	Jun. 22, 2021	Mar. 30, 2021	Aug. 13, 2019
Asset Coverage to Borrowings, Ratio, Percent			172%
Restricted Investments			$ 2,987			$ 2,788
Long-Term Debt, Gross			444,541			439,323
Debt Instrument, Face Amount			$ 577,791			582,573
Key Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature									$ 150,000
Line of Credit Facility, Maximum Borrowing Capacity									$ 125,000
Line of Credit Facility, Advance Rate of Eligible Debt Investments									60%
Long-Term Debt, Weighted Average Interest Rate, over Time			7.94%	4.25%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage			0.50%
Line of Credit Facility, Current Borrowing Capacity			$ 110,000			120,000
Line of Credit Facility, Remaining Borrowing Capacity			47,700			40,200
Long-Term Debt, Gross			15,000			5,000
Debt Instrument, Face Amount			$ 125,000			$ 125,000
Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			0.25%
Debt Instrument, Variable Rate			8%			7.50%
NYL Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 200,000	$ 100,000			$ 200,000
Line of Credit Facility, Current Borrowing Capacity			$ 23,200			$ 23,200
Line of Credit Facility, Remaining Borrowing Capacity			21,100			23,200
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature		$ 200,000
Line of Credit Facility, Advance Rate		67%
Line of Credit Facility, Change in Maximum Borrowing Capacity	$ 100,000
Long-Term Line of Credit			$ 176,800			$ 176,800
Line of Credit Facility, Interest Rate at Period End			5.57%			5.57%
Restricted Investments			$ 1,300			$ 1,000
Long-Term Debt, Gross			176,750			176,750
Debt Instrument, Face Amount			200,000			200,000
NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate					3%
Asset-backed Notes 2019 [Member]
Restricted Investments			500			600
Debt Instrument, Interest Rate, Stated Percentage											4.21%
Long-Term Debt, Gross			37,791			42,573
Debt Instrument, Face Amount			37,791			42,573					$ 160,000
Asset-backed Notes 2022 [Member]
Restricted Investments			1,100			1,000
Debt Instrument, Interest Rate, Stated Percentage							7.56%
Long-Term Debt, Gross			100,000			100,000
Debt Instrument, Face Amount			100,000			100,000	$ 157,800
The 2026 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage										4.875%
Long-Term Debt, Gross			57,500			57,500
Debt Instrument, Face Amount			57,500			57,500				$ 57,500
The 2026 Notes Underwriter Option [Member]
Debt Instrument, Face Amount										$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)										$ 25
The 2027 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage								6.25%
Long-Term Debt, Gross			57,500			57,500
Debt Instrument, Face Amount			$ 57,500			$ 57,500		$ 50,000
The 2027 Notes Underwriter Option [Member]
Debt Instrument, Face Amount								$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)								$ 25
Minimum [Member]
Asset Coverage to Borrowings, Ratio, Percent			150%
Minimum [Member] | Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			4.25%
Minimum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		3.55%
Maximum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		5.15%

Note 7 - Borrowings - Borrowing

Note 7 - Borrowings - Borrowings (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Nov. 09, 2022	Jun. 15, 2022	Mar. 30, 2021	Aug. 13, 2019
Total commitment	$ 577,791	$ 582,573
Balance outstanding	444,541	439,323
Unused commitment	133,250	143,250
Unamortized debt issuance costs attributable to term borrowings	(4,896)	(5,245)
Total borrowings outstanding, net	439,645	434,078
Key Facility [Member]
Total commitment	125,000	125,000
Balance outstanding	15,000	5,000
Unused commitment	110,000	120,000
NYL Facility [Member]
Total commitment	200,000	200,000
Balance outstanding	176,750	176,750
Unused commitment	23,250	23,250
Asset-backed Notes 2019 [Member]
Total commitment	37,791	42,573				$ 160,000
Balance outstanding	37,791	42,573
Unused commitment	0	0
Asset-backed Notes 2022 [Member]
Total commitment	100,000	100,000	$ 157,800
Balance outstanding	100,000	100,000
Unused commitment	0	0
The 2027 Notes [Member]
Total commitment	57,500	57,500		$ 50,000
Balance outstanding	57,500	57,500
Unused commitment	0	0
The 2026 Notes [Member]
Total commitment	57,500	57,500			$ 57,500
Balance outstanding	57,500	57,500
Unused commitment	$ 0	$ 0

Note 8 - Financial Instrument_3

Note 8 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability	$ 1,496	$ 1,761
Commitments to Extend Credit [Member]
Other Commitment	$ 166,200	$ 190,000

Note 8 - Financial Instrument_4

Note 8 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Unfunded commitments, principal balance	$ 166,200	$ 190,000
Fair value of unfunded commitment liability	1,496	1,761
BrightInsight, Inc. [Member]
Unfunded commitments, principal balance	18,250	21,000
Fair value of unfunded commitment liability	241	278
Britecore Holdings, Inc. [Member]
Unfunded commitments, principal balance	0	5,000
Fair value of unfunded commitment liability	0	66
Castle Creek Biosciences [Member]
Unfunded commitments, principal balance	4,000	4,000
Fair value of unfunded commitment liability	72	72
Corinth Medtech, Inc [Member]
Unfunded commitments, principal balance	200	0
Fair value of unfunded commitment liability	0	0
Divergent Technologies, Inc. [Member]
Unfunded commitments, principal balance	18,750	22,500
Fair value of unfunded commitment liability	197	236
Engage3, LLC [Member]
Unfunded commitments, principal balance	8,000	8,000
Fair value of unfunded commitment liability	40	40
Groundspeed Analytics, Inc. [Member]
Unfunded commitments, principal balance	15,500	15,000
Fair value of unfunded commitment liability	150	150
Hound Labs, Inc. [Member]
Unfunded commitments, principal balance	7,500	7,500
Fair value of unfunded commitment liability	88	88
KSQ Therapeutics, Inc. [Member]
Unfunded commitments, principal balance	10,000	10,000
Fair value of unfunded commitment liability	100	100
Lytics, Inc. [Member]
Unfunded commitments, principal balance	4,000	5,000
Fair value of unfunded commitment liability	52	65
Native Microbials, Inc. [Member]
Unfunded commitments, principal balance	0	7,500
Fair value of unfunded commitment liability	0	72
Noodle Partners, Inc. [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	123	0
Optoro, Inc. [Member]
Unfunded commitments, principal balance	15,000	15,000
Fair value of unfunded commitment liability	38	38
PDS Biotechnology Corporation [Member]
Unfunded commitments, principal balance	10,000	10,000
Fair value of unfunded commitment liability	158	158
Robin Healthcare, Inc. [Member]
Unfunded commitments, principal balance	5,000	10,000
Fair value of unfunded commitment liability	50	100
Scientia Vascular, Inc. [Member]
Unfunded commitments, principal balance	10,000	10,000
Fair value of unfunded commitment liability	110	110
Slingshot Aerospace, Inc. [Member]
Unfunded commitments, principal balance	5,000	5,000
Fair value of unfunded commitment liability	63	64
Swift Health Systems Inc. [Member]
Unfunded commitments, principal balance	18,500	25,500
Fair value of unfunded commitment liability	0	105
Temperpack Technologies, Inc [Member]
Unfunded commitments, principal balance	6,500	9,000
Fair value of unfunded commitment liability	$ 14	$ 19

Note 9 - Concentrations of Cr_2

Note 9 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member] - Five Largest Debt Investments [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Investment Concentration Risk [Member]
Concentration Risk, Percentage	23%		23%
Investment Income Concentration Risk [Member]
Concentration Risk, Percentage	22%	26%

Note 10 - Distributions (Detail

Note 10 - Distributions (Details Textual) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)	$ 0.33
Earnings Per Share, Basic (in dollars per share)	0.46	$ 0.26
Earnings Per Share, Basic, Undistributed (in dollars per share)	$ 0.81

Note 10 - Distributions - Distr

Note 10 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Distributions declared per share (in dollars per share)	$ 0.33	$ 0.30		$ 1.28
Dividends, cash	$ 3,035			$ 32,659
Dividends, shares (in shares)	6,894			61,859
Dividends, stock	$ 81			$ 754
June 15, 2023 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)			$ 0.11
July 17, 2023 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)			0.11
First 2/23/2023 Dividend [Member]
Record date	May 18, 2023
Payment date	Jun. 14, 2023
Distributions declared per share (in dollars per share)	$ 0.11
Dividends, cash	$ 0
Dividends, shares (in shares)	0
Dividends, stock	$ 0
August 16, 2023 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)			$ 0.11
Second 2/23/2023 Dividend [Member]
Record date	Apr. 18, 2023
Payment date	May 16, 2023
Distributions declared per share (in dollars per share)	$ 0.11
Dividends, cash	$ 0
Dividends, shares (in shares)	0
Dividends, stock	$ 0
Third 2/23/2023 Dividend [Member]
Record date	Mar. 17, 2023
Payment date	Apr. 14, 2023
Distributions declared per share (in dollars per share)	$ 0.11
Dividends, cash	$ 3,035
Dividends, shares (in shares)	6,894
Dividends, stock	$ 81
First 10/28/2022 Dividend [Member]
Record date				Feb. 17, 2023
Payment date				Mar. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,040
Dividends, shares (in shares)				6,764
Dividends, stock				$ 75
Second 10/28/2022 Dividend [Member]
Record date				Jan. 18, 2023
Payment date				Feb. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,021
Dividends, shares (in shares)				5,754
Dividends, stock				$ 74
Third 10/28/2022 Dividend [Member]
Record date				Dec. 19, 2022
Payment date				Jan. 13, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 2,978
Dividends, shares (in shares)				5,618
Dividends, stock				$ 69
Fourth 10/28/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.05
Dividends, cash				$ 1,319
Dividends, shares (in shares)				2,171
Dividends, stock				$ 27
First 7/29/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,638
Dividends, shares (in shares)				4,341
Dividends, stock				$ 57
Second 7/29/2022 Dividend [Member]
Record date				Oct. 18, 2022
Payment date				Nov. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,580
Dividends, shares (in shares)				4,621
Dividends, stock				$ 60
Third 7/29/2022 Dividend [Member]
Record date				Sep. 19, 2022
Payment date				Oct. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,558
Dividends, shares (in shares)				7,703
Dividends, stock				$ 81
First 4/29/22 Dividend [Member]
Record date				Aug. 18, 2022
Payment date				Sep. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,528
Dividends, shares (in shares)				4,925
Dividends, stock				$ 60
Second 4/29/2022 Dividend [Member]
Record date				Jul. 19, 2022
Payment date				Aug. 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,484
Dividends, shares (in shares)				3,939
Dividends, stock				$ 55
Third 4/29/2022 Dividend [Member]
Record date				Jun. 17, 2022
Payment date				Jul. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,434
Dividends, shares (in shares)				4,286
Dividends, stock				$ 51
First 2/25/2022 Dividend [Member]
Record date				May 18, 2022
Payment date				Jun. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,378
Dividends, shares (in shares)				4,428
Dividends, stock				$ 50
Second 2/25/2022 Dividend [Member]
Record date				Apr. 19, 2022
Payment date				May 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,349
Dividends, shares (in shares)				4,088
Dividends, stock				$ 49
Third 2/25/2022 Dividend [Member]
Record date				Mar. 18, 2022
Payment date				Apr. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,352
Dividends, shares (in shares)				3,221
Dividends, stock				$ 46

Note 11 - Financial Highlight_2

Note 11 - Financial Highlights - Financial Highlights (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Net asset value at beginning of period (in dollars per share)		$ 11.47	$ 11.56
Net investment income (in dollars per share)		0.46	0.26
Realized loss (in dollars per share)		(0.01)	0
Unrealized depreciation on investments (in dollars per share)		(0.26)	(0.10)
Net increase in net assets resulting from operations (in dollars per share)		0.19	0.16
Distributions declared (in dollars per share)	[1]	(0.33)	(0.30)
From net investment income (in dollars per share)		(0.33)	(0.30)
From net realized gain on investments (in dollars per share)		0	0
Return of capital (in dollars per share)		0	0
Other (in dollars per share)	[2]	0.01	0.26
Net asset value at end of period (in dollars per share)		11.34	11.68
Per share market value, beginning of period (in dollars per share)		11.60	15.92
Per share market value, end of period (in dollars per share)		$ 11.28	$ 13.90
Total return based on a market value	[3]	0.10%	(10.80%)
Shares outstanding at end of period (in shares)		28,377,357	23,977,137	27,753,373
Expenses without incentive value	[4]	14.80%	10.60%
Incentive fees	[4]	3.70%	2.20%
Net expenses	[4]	18.50%	12.80%
Net investment income with incentive fees	[4]	16.30%	8.70%
Net assets at the end of the period		$ 321,683	$ 279,989	$ 318,448
Average net asset value		$ 320,066	$ 262,662
Average debt per share (in dollars per share)		$ 15.61	$ 12.21
Portfolio turnover ratio	[5]	4.20%	2.60%
[1]Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.[2]Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.[3]The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.[4]Annualized.[5]Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance.

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2023	Mar. 31, 2023	Mar. 31, 2022
Proceeds from Issuance of Common Stock		$ 7,174	$ 38,187
The 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		605,848	250,171
Proceeds from Issuance of Common Stock		$ 7,200	$ 3,900
Payments of Stock Issuance Costs		$ 200	$ 100
Subsequent Event [Member] | The 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	272,303
Proceeds from Issuance of Common Stock	$ 3,100
Payments of Stock Issuance Costs	$ 100